Testhyperlink123: Difference between revisions
Jump to navigation
Jump to search
Guptareeya53 (talk | contribs) No edit summary |
Guptareeya53 (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2579390 2579390]|[https://pubmed.ncbi.nlm.nih.gov/19756298 19756298] <br> | ||
'''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br> | '''definition''' : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665] <br> | ||
'''term_xref''' : GTC:G44060QH|CHEBI:85665|CID: | '''term_xref''' : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040 <br> | ||
'''synonyms''' : Blood group A1 (type 3)|Blood Group A1 <br> | '''synonyms''' : Blood group A1 (type 3)|Blood Group A1 <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 23: | Line 23: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]|[https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3944091 3944091]|[https://pubmed.ncbi.nlm.nih.gov/29000000 29000000]|[https://pubmed.ncbi.nlm.nih.gov/28658771 28658771] <br> | ||
'''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br> | '''definition''' : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543] <br> | ||
'''term_xref''' : CHEBI:152543|CID: | '''term_xref''' : CHEBI:152543|CID: 91852328|GlycoMotif:GGM.000041|GTC:G62735WZ <br> | ||
'''synonyms''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br> | '''synonyms''' : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 36: | Line 36: | ||
'''glycan_dictionary_accession''' : GSD000033 <br> | '''glycan_dictionary_accession''' : GSD000033 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31734OS G31734OS] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G31734OS G31734OS] <br> | ||
'''term_in_sentence''' : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: | '''term_in_sentence''' : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: [https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/24749871 24749871]|[https://pubmed.ncbi.nlm.nih.gov/19387828 19387828]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/29562255 29562255] <br> | ||
'''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br> | '''definition''' : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID: | '''term_xref''' : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242 <br> | ||
'''synonyms''' : blood group B type 1 tetrasaccharide <br> | '''synonyms''' : blood group B type 1 tetrasaccharide <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 51: | Line 51: | ||
'''glycan_dictionary_accession''' : GSD000034 <br> | '''glycan_dictionary_accession''' : GSD000034 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G34881WK G34881WK] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G34881WK G34881WK] <br> | ||
'''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID: | '''term_in_sentence''' : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 <br> | '''term_xref''' : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262 <br> | ||
Line 67: | Line 67: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25216QA G25216QA] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G25216QA G25216QA] <br> | ||
'''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]] <br> | '''term_in_sentence''' : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1390942 1390942]|[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000087|GTC:G25216QA <br> | '''term_xref''' : GlycoMotif:GGM.000087|GTC:G25216QA <br> | ||
Line 82: | Line 82: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00294TN G00294TN] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00294TN G00294TN] <br> | ||
'''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]] <br> | '''term_in_sentence''' : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:[https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/6309836 6309836]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7718581 7718581]|[https://pubmed.ncbi.nlm.nih.gov/6309836 6309836]|[https://pubmed.ncbi.nlm.nih.gov/19208633 19208633]|[https://pubmed.ncbi.nlm.nih.gov/27431816 27431816]| [https://pubmed.ncbi.nlm.nih.gov/2432062 2432062]|[https://pubmed.ncbi.nlm.nih.gov/24219248 24219248]|[https://pubmed.ncbi.nlm.nih.gov/6352465 6352465]|[https://pubmed.ncbi.nlm.nih.gov/8499478 8499478]|[https://pubmed.ncbi.nlm.nih.gov/3348768 3348768]|[https://pubmed.ncbi.nlm.nih.gov/3718924 3718924] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br> | '''term_xref''' : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153 <br> | ||
Line 97: | Line 97: | ||
'''glycan_dictionary_accession''' : GSD000037 <br> | '''glycan_dictionary_accession''' : GSD000037 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G70519XK G70519XK] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G70519XK G70519XK] <br> | ||
'''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID: | '''term_in_sentence''' : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9405495 9405495]|[https://pubmed.ncbi.nlm.nih.gov/8082855 8082855]|[https://pubmed.ncbi.nlm.nih.gov/6177241 6177241]|[https://pubmed.ncbi.nlm.nih.gov/3944092 3944092]|[https://pubmed.ncbi.nlm.nih.gov/21406562 21406562]|[https://pubmed.ncbi.nlm.nih.gov/2410664 2410664]|[https://pubmed.ncbi.nlm.nih.gov/8731502 8731502]|[https://pubmed.ncbi.nlm.nih.gov/6203846 6203846]|[https://pubmed.ncbi.nlm.nih.gov/2238560 2238560]| <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G70519XK|GlycoMotif:GGM.000036 <br> | '''term_xref''' : GTC:G70519XK|GlycoMotif:GGM.000036 <br> | ||
Line 116: | Line 116: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11479278 11479278] <br> | ||
'''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br> | '''definition''' : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045] <br> | ||
'''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID: | '''term_xref''' : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045 <br> | ||
'''synonyms''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br> | '''synonyms''' : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y <br> | ||
'''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br> | '''function''' : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018] <br> | ||
Line 128: | Line 128: | ||
'''glycan_dictionary_accession''' : GSD000039 <br> | '''glycan_dictionary_accession''' : GSD000039 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98465JN G98465JN] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98465JN G98465JN] <br> | ||
'''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID: | '''term_in_sentence''' : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11261842 11261842]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11261842 11261842]| [https://pubmed.ncbi.nlm.nih.gov/1841684 1841684]|[https://pubmed.ncbi.nlm.nih.gov/11101633 11101633]|[https://pubmed.ncbi.nlm.nih.gov/9405495 9405495] <br> | ||
'''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br> | '''definition''' : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID: | '''term_xref''' : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245<br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 146: | Line 146: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]|[https://pubmed.ncbi.nlm.nih.gov/19267921 19267921]|[https://pubmed.ncbi.nlm.nih.gov/21283832 21283832]|[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]|[https://pubmed.ncbi.nlm.nih.gov/17072011 17072011] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12736247 12736247]|[https://pubmed.ncbi.nlm.nih.gov/19267921 19267921]|[https://pubmed.ncbi.nlm.nih.gov/21283832 21283832]|[https://pubmed.ncbi.nlm.nih.gov/15596301 15596301]|[https://pubmed.ncbi.nlm.nih.gov/17072011 17072011] <br> | ||
'''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br> | '''definition''' : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID: | '''term_xref''' : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 160: | Line 160: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G04416BG G04416BG] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G04416BG G04416BG] <br> | ||
'''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br> | '''term_in_sentence''' : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074] <br> | ||
'''publication''' : 818074 <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/818074 818074] <br> | ||
'''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/<nowiki>] </nowiki><br> | '''definition''' : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/<nowiki>] </nowiki><br> | ||
'''term_xref''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br> | '''term_xref''' : GTC:G04416BG|GlycoMotif:GGM.000065 <br> | ||
Line 175: | Line 175: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]] <br> | '''term_in_sentence''' : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31013685 31013685]|[https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]|[https://pubmed.ncbi.nlm.nih.gov/27194526 27194526]|[https://pubmed.ncbi.nlm.nih.gov/26980567 26980567]|[https://pubmed.ncbi.nlm.nih.gov/28847361 28847361]|[https://pubmed.ncbi.nlm.nih.gov/24413804 24413804]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/29600622 29600622]|[https://pubmed.ncbi.nlm.nih.gov/25129732 25129732]|[https://pubmed.ncbi.nlm.nih.gov/31317901 31317901]|[https://pubmed.ncbi.nlm.nih.gov/29181550 29181550]|[https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]|[https://pubmed.ncbi.nlm.nih.gov/22265655 22265655]|[https://pubmed.ncbi.nlm.nih.gov/25756648 25756648]|[https://pubmed.ncbi.nlm.nih.gov/29402610 29402610]|[https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/20236040 20236040]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/30824935 30824935]|[https://pubmed.ncbi.nlm.nih.gov/26572336 26572336]|[https://pubmed.ncbi.nlm.nih.gov/31207331 31207331]|[https://pubmed.ncbi.nlm.nih.gov/21110089 21110089]|[https://pubmed.ncbi.nlm.nih.gov/30599999 30599999]|[https://pubmed.ncbi.nlm.nih.gov/20399897 20399897]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/19388612 19388612]|[https://pubmed.ncbi.nlm.nih.gov/23186102 23186102]|[https://pubmed.ncbi.nlm.nih.gov/31494830 31494830]|[https://pubmed.ncbi.nlm.nih.gov/28982096 28982096]|[https://pubmed.ncbi.nlm.nih.gov/30241863 30241863]|[https://pubmed.ncbi.nlm.nih.gov/30295666 30295666]|[https://pubmed.ncbi.nlm.nih.gov/25366475 25366475]|[https://pubmed.ncbi.nlm.nih.gov/20521042 20521042]|[https://pubmed.ncbi.nlm.nih.gov/29456007 29456007]|[https://pubmed.ncbi.nlm.nih.gov/31304829 31304829]|[https://pubmed.ncbi.nlm.nih.gov/18661362 18661362]|[https://pubmed.ncbi.nlm.nih.gov/28576008 28576008]|[https://pubmed.ncbi.nlm.nih.gov/29494632 29494632]|[https://pubmed.ncbi.nlm.nih.gov/30016441 30016441]|[https://pubmed.ncbi.nlm.nih.gov/26906924 26906924]|[https://pubmed.ncbi.nlm.nih.gov/24861964 24861964]|[https://pubmed.ncbi.nlm.nih.gov/23774590 23774590]|[https://pubmed.ncbi.nlm.nih.gov/31887904 31887904]|[https://pubmed.ncbi.nlm.nih.gov/31339761 31339761]| [https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]|[https://pubmed.ncbi.nlm.nih.gov/26957048 26957048]|[https://pubmed.ncbi.nlm.nih.gov/29625000 29625000] <br> | ||
'''definition''' : Any of a class of 10—60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br> | '''definition''' : Any of a class of 10—60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397] <br> | ||
'''term_xref''' : CHEBI:37397|CID:24766 <br> | '''term_xref''' : CHEBI:37397|CID:24766 <br> | ||
Line 192: | Line 192: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9455923 9455923] <br> | ||
'''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br> | '''definition''' : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID: | '''term_xref''' : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125 <br> | ||
'''synonyms''' : GM1b <br> | '''synonyms''' : GM1b <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 204: | Line 204: | ||
'''glycan_dictionary_accession''' : GSD000045 <br> | '''glycan_dictionary_accession''' : GSD000045 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252] <br> | '''term_in_sentence''' : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29902282 29902282]|[https://pubmed.ncbi.nlm.nih.gov/29212795 29212795]|[https://pubmed.ncbi.nlm.nih.gov/29343819 29343819]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/26745022 26745022]|[https://pubmed.ncbi.nlm.nih.gov/18399796 18399796]|[https://pubmed.ncbi.nlm.nih.gov/16825488 16825488]|[https://pubmed.ncbi.nlm.nih.gov/21964725 21964725]|[https://pubmed.ncbi.nlm.nih.gov/15864431 15864431]|[https://pubmed.ncbi.nlm.nih.gov/22890903 22890903]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/28039392 28039392]|[https://pubmed.ncbi.nlm.nih.gov/19426135 19426135]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/16794314 16794314]|[https://pubmed.ncbi.nlm.nih.gov/19806620 19806620]|[https://pubmed.ncbi.nlm.nih.gov/22975979 22975979]|[https://pubmed.ncbi.nlm.nih.gov/25931033 25931033]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/19129634 19129634]|[https://pubmed.ncbi.nlm.nih.gov/19129628 19129628]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/31021709 31021709]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/28091941 28091941]|[https://pubmed.ncbi.nlm.nih.gov/23115339 23115339]|[https://pubmed.ncbi.nlm.nih.gov/20829342 20829342]|[https://pubmed.ncbi.nlm.nih.gov/27304954 27304954]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29902282 29902282]|[https://pubmed.ncbi.nlm.nih.gov/29212795 29212795]|[https://pubmed.ncbi.nlm.nih.gov/29343819 29343819]|[https://pubmed.ncbi.nlm.nih.gov/27705835 27705835]|[https://pubmed.ncbi.nlm.nih.gov/26745022 26745022]|[https://pubmed.ncbi.nlm.nih.gov/18399796 18399796]|[https://pubmed.ncbi.nlm.nih.gov/16825488 16825488]|[https://pubmed.ncbi.nlm.nih.gov/21964725 21964725]|[https://pubmed.ncbi.nlm.nih.gov/15864431 15864431]|[https://pubmed.ncbi.nlm.nih.gov/22890903 22890903]|[https://pubmed.ncbi.nlm.nih.gov/12417032 12417032]|[https://pubmed.ncbi.nlm.nih.gov/28039392 28039392]|[https://pubmed.ncbi.nlm.nih.gov/19426135 19426135]|[https://pubmed.ncbi.nlm.nih.gov/30253927 30253927]|[https://pubmed.ncbi.nlm.nih.gov/16794314 16794314]|[https://pubmed.ncbi.nlm.nih.gov/19806620 19806620]|[https://pubmed.ncbi.nlm.nih.gov/22975979 22975979]|[https://pubmed.ncbi.nlm.nih.gov/25931033 25931033]|[https://pubmed.ncbi.nlm.nih.gov/15201278 15201278]|[https://pubmed.ncbi.nlm.nih.gov/19129634 19129634]|[https://pubmed.ncbi.nlm.nih.gov/19129628 19129628]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/31021709 31021709]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]|[https://pubmed.ncbi.nlm.nih.gov/28091941 28091941]|[https://pubmed.ncbi.nlm.nih.gov/23115339 23115339]|[https://pubmed.ncbi.nlm.nih.gov/20829342 20829342]|[https://pubmed.ncbi.nlm.nih.gov/27304954 27304954]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/21802690 21802690]|[https://pubmed.ncbi.nlm.nih.gov/29725121 29725121]|[https://pubmed.ncbi.nlm.nih.gov/30471292 30471292]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26098720 26098720]|[https://pubmed.ncbi.nlm.nih.gov/31080188 31080188]|[https://pubmed.ncbi.nlm.nih.gov/1930135 1930135]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/30844485 30844485]|[https://pubmed.ncbi.nlm.nih.gov/24014058 24014058]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583] <br> | ||
'''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | '''definition''' : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
Line 222: | Line 222: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]|[https://pubmed.ncbi.nlm.nih.gov/30315106 30315106]|[https://pubmed.ncbi.nlm.nih.gov/23640779 23640779]|[https://pubmed.ncbi.nlm.nih.gov/26677400 26677400] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19349303 19349303]|[https://pubmed.ncbi.nlm.nih.gov/30315106 30315106]|[https://pubmed.ncbi.nlm.nih.gov/23640779 23640779]|[https://pubmed.ncbi.nlm.nih.gov/26677400 26677400] <br> | ||
'''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br> | '''definition''' : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158] <br> | ||
'''term_xref''' : GTC:G00033MO|CID: | '''term_xref''' : GTC:G00033MO|CID: 52921656|CHEBI:62158 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 237: | Line 237: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]|[https://pubmed.ncbi.nlm.nih.gov/27259834 27259834]|[https://pubmed.ncbi.nlm.nih.gov/27143302 27143302]| <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28745318 28745318]|[https://pubmed.ncbi.nlm.nih.gov/27259834 27259834]|[https://pubmed.ncbi.nlm.nih.gov/27143302 27143302]| <br> | ||
'''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br> | '''definition''' : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344] <br> | ||
'''term_xref''' : GTC:G00035MO|CID: | '''term_xref''' : GTC:G00035MO|CID:25061208|CHEBI:71344 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 252: | Line 252: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]|[https://pubmed.ncbi.nlm.nih.gov/10747980 10747980]| <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9988682 9988682]|[https://pubmed.ncbi.nlm.nih.gov/10747980 10747980]| <br> | ||
'''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br> | '''definition''' : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341] <br> | ||
'''term_xref''' : GTC:G00037MO| CID: | '''term_xref''' : GTC:G00037MO| CID:25229562|CHEBI:71341 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 266: | Line 266: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78059CC G78059CC] <br> | ||
'''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]] <br> | '''term_in_sentence''' : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:[https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27678371 27678371]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]|[https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]| [https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/28674882 28674882]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/27798819 27798819]|[https://pubmed.ncbi.nlm.nih.gov/32044029 32044029]|[https://pubmed.ncbi.nlm.nih.gov/30962950 30962950]|[https://pubmed.ncbi.nlm.nih.gov/31548313 31548313]|[https://pubmed.ncbi.nlm.nih.gov/30907281 30907281]|[https://pubmed.ncbi.nlm.nih.gov/29090617 29090617]|[https://pubmed.ncbi.nlm.nih.gov/29571940 29571940]|[https://pubmed.ncbi.nlm.nih.gov/28800497 28800497]|[https://pubmed.ncbi.nlm.nih.gov/27629418 27629418]|[https://pubmed.ncbi.nlm.nih.gov/29733746 29733746]|[https://pubmed.ncbi.nlm.nih.gov/31623829 31623829]|[https://pubmed.ncbi.nlm.nih.gov/28768188 28768188]|[https://pubmed.ncbi.nlm.nih.gov/26897254 26897254]|[https://pubmed.ncbi.nlm.nih.gov/31451706 31451706]|[https://pubmed.ncbi.nlm.nih.gov/26514868 26514868]]|[https://pubmed.ncbi.nlm.nih.gov/29427759 29427759]|[https://pubmed.ncbi.nlm.nih.gov/28982386 28982386]|[https://pubmed.ncbi.nlm.nih.gov/26587313 26587313]|[https://pubmed.ncbi.nlm.nih.gov/30940702 30940702]| [https://pubmed.ncbi.nlm.nih.gov/15538974 15538974]|[https://pubmed.ncbi.nlm.nih.gov/31249452 31249452]|[https://pubmed.ncbi.nlm.nih.gov/27282921 27282921]|[https://pubmed.ncbi.nlm.nih.gov/31229844 31229844]|[https://pubmed.ncbi.nlm.nih.gov/30445455 30445455]|[https://pubmed.ncbi.nlm.nih.gov/31325506 31325506]|[https://pubmed.ncbi.nlm.nih.gov/24732908 24732908]|[https://pubmed.ncbi.nlm.nih.gov/29209018 29209018]|[https://pubmed.ncbi.nlm.nih.gov/26965517 26965517]|[https://pubmed.ncbi.nlm.nih.gov/28609658 28609658]| [https://pubmed.ncbi.nlm.nih.gov/24914453 24914453]|[https://pubmed.ncbi.nlm.nih.gov/25573275 25573275]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/19218400 19218400]|[https://pubmed.ncbi.nlm.nih.gov/27012207 27012207]|[https://pubmed.ncbi.nlm.nih.gov/27139574 27139574]| [https://pubmed.ncbi.nlm.nih.gov/32078267 32078267]|[https://pubmed.ncbi.nlm.nih.gov/25861849 25861849]|[https://pubmed.ncbi.nlm.nih.gov/32561391 32561391]|[https://pubmed.ncbi.nlm.nih.gov/21374780 21374780]|[https://pubmed.ncbi.nlm.nih.gov/31669139 31669139]|[https://pubmed.ncbi.nlm.nih.gov/25732060 25732060]|[https://pubmed.ncbi.nlm.nih.gov/29408166 29408166]|[https://pubmed.ncbi.nlm.nih.gov/31268672 31268672]|[https://pubmed.ncbi.nlm.nih.gov/30472795 30472795]|[https://pubmed.ncbi.nlm.nih.gov/30614075 30614075]|[https://pubmed.ncbi.nlm.nih.gov/19003000 19003000]|[https://pubmed.ncbi.nlm.nih.gov/25664929 25664929] <br> | ||
'''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006<nowiki>]. </nowiki><br> | '''definition''' : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006<nowiki>]. </nowiki><br> | ||
'''term_xref''' : GTC:G78059CC|CID: | '''term_xref''' : GTC:G78059CC|CID: 70679232|CHEBI:70967|CHEBI:156499 <br> | ||
'''synonyms''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br> | '''synonyms''' : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc <br> | ||
'''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br> | '''function''' : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024] <br> | ||
Line 283: | Line 283: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/22256781 22256781]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/25855029 25855029]|[https://pubmed.ncbi.nlm.nih.gov/10529240 10529240]|[https://pubmed.ncbi.nlm.nih.gov/26544759 26544759]|[https://pubmed.ncbi.nlm.nih.gov/8206921 8206921]|[https://pubmed.ncbi.nlm.nih.gov/33149259 33149259]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9654101 9654101]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/28263871 28263871]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/22256781 22256781]|[https://pubmed.ncbi.nlm.nih.gov/23681398 23681398]|[https://pubmed.ncbi.nlm.nih.gov/25855029 25855029]|[https://pubmed.ncbi.nlm.nih.gov/10529240 10529240]|[https://pubmed.ncbi.nlm.nih.gov/26544759 26544759]|[https://pubmed.ncbi.nlm.nih.gov/8206921 8206921]|[https://pubmed.ncbi.nlm.nih.gov/33149259 33149259]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276] <br> | ||
'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br> | '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br> | ||
'''term_xref''' : GTC:G78059CC|CID: | '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br> | ||
'''synonyms''' : core-fucosylated diantennary <br> | '''synonyms''' : core-fucosylated diantennary <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 298: | Line 298: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10731668 10731668] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10731668 10731668] <br> | ||
'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br> | '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc. <br> | ||
'''term_xref''' : GTC:G78059CC|CID: | '''term_xref''' : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499 <br> | ||
'''synonyms''' : core fucosylated diantennary complex-type <br> | '''synonyms''' : core fucosylated diantennary complex-type <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 314: | Line 314: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/31222115 31222115]|[https://pubmed.ncbi.nlm.nih.gov/9990070 9990070]|[https://pubmed.ncbi.nlm.nih.gov/23088960 23088960] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/31222115 31222115]|[https://pubmed.ncbi.nlm.nih.gov/9990070 9990070]|[https://pubmed.ncbi.nlm.nih.gov/23088960 23088960] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoEpitope:EP0017|CID: | '''term_xref''' : GlycoEpitope:EP0017|CID: 91858084|CHEBI:147484<br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br> | '''function''' : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017] <br> | ||
Line 327: | Line 327: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G57710SU G57710SU] <br> | ||
'''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]] <br> | '''term_in_sentence''' : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]] <br> | ||
'''publication''' : 893368|[https://pubmed.ncbi.nlm.nih.gov/4375678 4375678]|51702|186204|[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]|[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]|[https://pubmed.ncbi.nlm.nih.gov/24174198 24174198]|[https://pubmed.ncbi.nlm.nih.gov/6072378 6072378]|389925|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/893368 893368]|[https://pubmed.ncbi.nlm.nih.gov/4375678 4375678]|[https://pubmed.ncbi.nlm.nih.gov/51702 51702]|[https://pubmed.ncbi.nlm.nih.gov/186204 186204]|[https://pubmed.ncbi.nlm.nih.gov/4110375 4110375]|[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]|[https://pubmed.ncbi.nlm.nih.gov/24174198 24174198]|[https://pubmed.ncbi.nlm.nih.gov/6072378 6072378]|[https://pubmed.ncbi.nlm.nih.gov/389925 389925|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174] <br> | ||
'''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]] <br> | '''definition''' : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:[https://pubmed.ncbi.nlm.nih.gov/5068000 5068000]] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID: | '''term_xref''' : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 342: | Line 342: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]] <br> | '''term_in_sentence''' : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27526113 27526113]]|[https://pubmed.ncbi.nlm.nih.gov/29111696 29111696]|[https://pubmed.ncbi.nlm.nih.gov/29891297 29891297]|[https://pubmed.ncbi.nlm.nih.gov/26164146 26164146]|[https://pubmed.ncbi.nlm.nih.gov/30869126 30869126]|[https://pubmed.ncbi.nlm.nih.gov/7789716 7789716]|[https://pubmed.ncbi.nlm.nih.gov/8597249 8597249]|[https://pubmed.ncbi.nlm.nih.gov/12512856 12512856]| [https://pubmed.ncbi.nlm.nih.gov/31250530 31250530]| [https://pubmed.ncbi.nlm.nih.gov/17928217 17928217]|[https://pubmed.ncbi.nlm.nih.gov/12213784 12213784]|[https://pubmed.ncbi.nlm.nih.gov/27226567 27226567]|[https://pubmed.ncbi.nlm.nih.gov/31455633 31455633]|[https://pubmed.ncbi.nlm.nih.gov/28091940 28091940]|[https://pubmed.ncbi.nlm.nih.gov/19075609 19075609]|[https://pubmed.ncbi.nlm.nih.gov/31071403 31071403]|[https://pubmed.ncbi.nlm.nih.gov/15078125 15078125]|[https://pubmed.ncbi.nlm.nih.gov/18661328 18661328]|[https://pubmed.ncbi.nlm.nih.gov/20581662 20581662]|[https://pubmed.ncbi.nlm.nih.gov/17239765 17239765]|[https://pubmed.ncbi.nlm.nih.gov/15749837 15749837]|[https://pubmed.ncbi.nlm.nih.gov/2777747 2777747]|[https://pubmed.ncbi.nlm.nih.gov/20632047 20632047]|[https://pubmed.ncbi.nlm.nih.gov/8930750 8930750]|[https://pubmed.ncbi.nlm.nih.gov/7762784 7762784]|[https://pubmed.ncbi.nlm.nih.gov/31006321 31006321]|[https://pubmed.ncbi.nlm.nih.gov/26876822 26876822]|[https://pubmed.ncbi.nlm.nih.gov/1522290 1522290]|131009|[https://pubmed.ncbi.nlm.nih.gov/26986023 26986023]|[https://pubmed.ncbi.nlm.nih.gov/8161353 8161353]|[https://pubmed.ncbi.nlm.nih.gov/15315969 15315969]|[https://pubmed.ncbi.nlm.nih.gov/12543559 12543559]|[https://pubmed.ncbi.nlm.nih.gov/30637950 30637950]|[https://pubmed.ncbi.nlm.nih.gov/2525357 2525357]|[https://pubmed.ncbi.nlm.nih.gov/18156656 18156656]|[https://pubmed.ncbi.nlm.nih.gov/9692613 9692613]|[https://pubmed.ncbi.nlm.nih.gov/9200333 9200333]|[https://pubmed.ncbi.nlm.nih.gov/19661164 19661164]|[https://pubmed.ncbi.nlm.nih.gov/2299256 2299256]|[https://pubmed.ncbi.nlm.nih.gov/16075147 16075147]|[https://pubmed.ncbi.nlm.nih.gov/1126924 1126924]|[https://pubmed.ncbi.nlm.nih.gov/9774430 9774430]|[https://pubmed.ncbi.nlm.nih.gov/8537360 8537360]|[https://pubmed.ncbi.nlm.nih.gov/15563459 15563459]|[https://pubmed.ncbi.nlm.nih.gov/21077227 21077227]|[https://pubmed.ncbi.nlm.nih.gov/23275130 23275130]|[https://pubmed.ncbi.nlm.nih.gov/17137817 17137817]|[https://pubmed.ncbi.nlm.nih.gov/6447930 6447930]|[https://pubmed.ncbi.nlm.nih.gov/6209270 6209270] <br> | ||
'''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] <br> | '''definition''' : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376] <br> | ||
'''term_xref''' : CHEBI:18376|CID:32756 <br> | '''term_xref''' : CHEBI:18376|CID:32756 <br> | ||
Line 386: | Line 386: | ||
'''glycan_dictionary_accession''' : GSD000057 <br> | '''glycan_dictionary_accession''' : GSD000057 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID: | '''term_in_sentence''' : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID: [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] <br> | ||
'''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br> | '''definition''' : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
'''disease_associations''' : pancreatic cancer[PMID: | '''disease_associations''' : pancreatic cancer[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]] <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
'''essentials_of_glycobiology''' : <br> | '''essentials_of_glycobiology''' : <br> | ||
Line 404: | Line 404: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/12062524 12062524]|[https://pubmed.ncbi.nlm.nih.gov/15488731 15488731]|[https://pubmed.ncbi.nlm.nih.gov/1979361 1979361]|[https://pubmed.ncbi.nlm.nih.gov/8737237 8737237]|[https://pubmed.ncbi.nlm.nih.gov/17939723 17939723]|[https://pubmed.ncbi.nlm.nih.gov/7683631 7683631]|[https://pubmed.ncbi.nlm.nih.gov/11384108 11384108]|[https://pubmed.ncbi.nlm.nih.gov/11133015 11133015]|[https://pubmed.ncbi.nlm.nih.gov/17388629 17388629]|[https://pubmed.ncbi.nlm.nih.gov/15483381 15483381]|[https://pubmed.ncbi.nlm.nih.gov/12662048 12662048]|[https://pubmed.ncbi.nlm.nih.gov/3233598 3233598]|[https://pubmed.ncbi.nlm.nih.gov/18618154 18618154]|[https://pubmed.ncbi.nlm.nih.gov/21892456 21892456] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32957489 32957489]|[https://pubmed.ncbi.nlm.nih.gov/31276881 31276881]|[https://pubmed.ncbi.nlm.nih.gov/12062524 12062524]|[https://pubmed.ncbi.nlm.nih.gov/15488731 15488731]|[https://pubmed.ncbi.nlm.nih.gov/1979361 1979361]|[https://pubmed.ncbi.nlm.nih.gov/8737237 8737237]|[https://pubmed.ncbi.nlm.nih.gov/17939723 17939723]|[https://pubmed.ncbi.nlm.nih.gov/7683631 7683631]|[https://pubmed.ncbi.nlm.nih.gov/11384108 11384108]|[https://pubmed.ncbi.nlm.nih.gov/11133015 11133015]|[https://pubmed.ncbi.nlm.nih.gov/17388629 17388629]|[https://pubmed.ncbi.nlm.nih.gov/15483381 15483381]|[https://pubmed.ncbi.nlm.nih.gov/12662048 12662048]|[https://pubmed.ncbi.nlm.nih.gov/3233598 3233598]|[https://pubmed.ncbi.nlm.nih.gov/18618154 18618154]|[https://pubmed.ncbi.nlm.nih.gov/21892456 21892456] <br> | ||
'''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br> | '''definition''' : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325] <br> | ||
'''term_xref''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID: | '''term_xref''' : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031 <br> | ||
'''synonyms''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br> | '''synonyms''' : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx <br> | ||
'''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br> | '''function''' : cancer-associated antigen[GlycoEpitope:EP0093] <br> | ||
Line 431: | Line 431: | ||
'''glycan_dictionary_accession''' : GSD000060 <br> | '''glycan_dictionary_accession''' : GSD000060 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br> | ||
'''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID: | '''term_in_sentence''' : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/24637536 24637536]|[https://pubmed.ncbi.nlm.nih.gov/25864532 25864532]|[https://pubmed.ncbi.nlm.nih.gov/27344728 27344728]| [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]| [https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]|[https://pubmed.ncbi.nlm.nih.gov/20663960 20663960]|[https://pubmed.ncbi.nlm.nih.gov/18214042 18214042] <br> | ||
'''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br> | '''definition''' : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID: | '''term_xref''' : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57 <br> | ||
'''synonyms''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br> | '''synonyms''' : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside <br> | ||
'''function''' : promotes metastasis[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br> | '''function''' : promotes metastasis[PMID:[https://pubmed.ncbi.nlm.nih.gov/28205070 28205070]] <br> | ||
Line 446: | Line 446: | ||
'''glycan_dictionary_accession''' : GSD000061 <br> | '''glycan_dictionary_accession''' : GSD000061 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G97932OH G97932OH] <br> | ||
'''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: | '''term_in_sentence''' : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoEpitope:EP0098|GTC:G97932OH|CID: | '''term_xref''' : GlycoEpitope:EP0098|GTC:G97932OH|CID: 91860287|SugarBind_Ligand:57|KEGG:G00181 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 464: | Line 464: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10640401 10640401] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10640401 10640401] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoEpitope:EP0095|GTC:G54937EM|CID: | '''term_xref''' : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523 <br> | ||
'''synonyms''' : disialyl-I <br> | '''synonyms''' : disialyl-I <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 479: | Line 479: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]|[https://pubmed.ncbi.nlm.nih.gov/12668106 12668106]|[https://pubmed.ncbi.nlm.nih.gov/30716533 30716533]|[https://pubmed.ncbi.nlm.nih.gov/32050430 32050430]|[https://pubmed.ncbi.nlm.nih.gov/22467657 22467657] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12668675 12668675]|[https://pubmed.ncbi.nlm.nih.gov/17760270 17760270]|[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]|[https://pubmed.ncbi.nlm.nih.gov/12668106 12668106]|[https://pubmed.ncbi.nlm.nih.gov/30716533 30716533]|[https://pubmed.ncbi.nlm.nih.gov/32050430 32050430]|[https://pubmed.ncbi.nlm.nih.gov/22467657 22467657] <br> | ||
'''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]] <br> | '''definition''' : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:[https://pubmed.ncbi.nlm.nih.gov/15231659 15231659]] <br> | ||
'''term_xref''' : GTC:G93400AK |GlycoEpitope:EP0040|CID: | '''term_xref''' : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549 <br> | ||
'''synonyms''' : disialyl Lea <br> | '''synonyms''' : disialyl Lea <br> | ||
'''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br> | '''function''' : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040] <br> | ||
Line 494: | Line 494: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/17974963 17974963]|[https://pubmed.ncbi.nlm.nih.gov/33242079 33242079]|[https://pubmed.ncbi.nlm.nih.gov/12645620 12645620]|[https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]|[https://pubmed.ncbi.nlm.nih.gov/26598643 26598643] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/17974963 17974963]|[https://pubmed.ncbi.nlm.nih.gov/33242079 33242079]|[https://pubmed.ncbi.nlm.nih.gov/12645620 12645620]|[https://pubmed.ncbi.nlm.nih.gov/15701648 15701648]|[https://pubmed.ncbi.nlm.nih.gov/26598643 26598643] <br> | ||
'''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br> | '''definition''' : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID: | '''term_xref''' : GlycoMotif:GGM.000014|GTC:G01614ZM|CID: 70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027 <br> | ||
'''synonyms''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br> | '''synonyms''' : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen <br> | ||
'''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br> | '''function''' : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023] <br> | ||
Line 507: | Line 507: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]] <br> | '''term_in_sentence''' : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/17171781 17171781]|[https://pubmed.ncbi.nlm.nih.gov/25022802 25022802]|[https://pubmed.ncbi.nlm.nih.gov/24812685 24812685]|[https://pubmed.ncbi.nlm.nih.gov/24780636 24780636]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/17171781 17171781]|[https://pubmed.ncbi.nlm.nih.gov/25022802 25022802]|[https://pubmed.ncbi.nlm.nih.gov/24812685 24812685]|[https://pubmed.ncbi.nlm.nih.gov/24780636 24780636]|[https://pubmed.ncbi.nlm.nih.gov/26582205 26582205]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/22978794 22978794]|[https://pubmed.ncbi.nlm.nih.gov/22594947 22594947]|[https://pubmed.ncbi.nlm.nih.gov/8486673 8486673]|[https://pubmed.ncbi.nlm.nih.gov/20356825 20356825]|[https://pubmed.ncbi.nlm.nih.gov/1634621 1634621]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/1472054 1472054]| [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/19579232 19579232]|[https://pubmed.ncbi.nlm.nih.gov/27943633 27943633] <br> | ||
'''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br> | '''definition''' : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
'''synonyms''' : disialylated diantennary <br> | '''synonyms''' : disialylated diantennary <br> | ||
'''function''' : appears in human transferrin[PMID: | '''function''' : appears in human transferrin[PMID: [https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br> | ||
'''disease_associations''' : galactosemia.[PMID: | '''disease_associations''' : galactosemia.[PMID: [https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
'''essentials_of_glycobiology''' : <br> | '''essentials_of_glycobiology''' : <br> | ||
Line 522: | Line 522: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]] <br> | '''term_in_sentence''' : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11738084 11738084]|[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]|[https://pubmed.ncbi.nlm.nih.gov/9244386 9244386]|[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]|[https://pubmed.ncbi.nlm.nih.gov/12966096 12966096]|[https://pubmed.ncbi.nlm.nih.gov/25124522 25124522]|[https://pubmed.ncbi.nlm.nih.gov/19371135 19371135] <br> | ||
'''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br> | '''definition''' : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : appears in human transferrin[PMID: | '''function''' : appears in human transferrin[PMID:[https://pubmed.ncbi.nlm.nih.gov/24243045 24243045]]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297] <br> | ||
'''disease_associations''' : galactosemia.[PMID: | '''disease_associations''' : galactosemia.[PMID:[https://pubmed.ncbi.nlm.nih.gov/9499382 9499382]] <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
'''essentials_of_glycobiology''' : <br> | '''essentials_of_glycobiology''' : <br> | ||
Line 551: | Line 551: | ||
'''glycan_dictionary_accession''' : GSD000068 <br> | '''glycan_dictionary_accession''' : GSD000068 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br> | ||
'''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution.[PMID:[https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]] <br> | '''term_in_sentence''' : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]|[https://pubmed.ncbi.nlm.nih.gov/31933576 31933576]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28510705 28510705]|[https://pubmed.ncbi.nlm.nih.gov/31933576 31933576]| [https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/7021748 7021748]|[https://pubmed.ncbi.nlm.nih.gov/1802714 1802714]|[https://pubmed.ncbi.nlm.nih.gov/7512587 7512587]|[https://pubmed.ncbi.nlm.nih.gov/7747818 7747818]|[https://pubmed.ncbi.nlm.nih.gov/23325748 23325748]|[https://pubmed.ncbi.nlm.nih.gov/268649 268649]|[https://pubmed.ncbi.nlm.nih.gov/31816281 31816281]|[https://pubmed.ncbi.nlm.nih.gov/22015168 22015168]|[https://pubmed.ncbi.nlm.nih.gov/4147161 4147161]|[https://pubmed.ncbi.nlm.nih.gov/2857159 2857159]|[https://pubmed.ncbi.nlm.nih.gov/6267170 6267170]|[https://pubmed.ncbi.nlm.nih.gov/7293775 7293775]|[https://pubmed.ncbi.nlm.nih.gov/13367419 13367419]|[https://pubmed.ncbi.nlm.nih.gov/20636540 20636540]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829] [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/23255552 23255552]|[https://pubmed.ncbi.nlm.nih.gov/2675268 2675268]|[https://pubmed.ncbi.nlm.nih.gov/18955372 18955372]|[https://pubmed.ncbi.nlm.nih.gov/7020692 7020692]|[https://pubmed.ncbi.nlm.nih.gov/31784953 31784953]|[https://pubmed.ncbi.nlm.nih.gov/4114942 4114942]|[https://pubmed.ncbi.nlm.nih.gov/31273262 31273262]|[https://pubmed.ncbi.nlm.nih.gov/6257673 6257673]|[https://pubmed.ncbi.nlm.nih.gov/7696847 7696847]|[https://pubmed.ncbi.nlm.nih.gov/1916901 1916901]|[https://pubmed.ncbi.nlm.nih.gov/11169215 11169215]|[https://pubmed.ncbi.nlm.nih.gov/48262 48262]|[https://pubmed.ncbi.nlm.nih.gov/26022515 26022515]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/31404475 31404475]|[https://pubmed.ncbi.nlm.nih.gov/6983878 6983878]|[https://pubmed.ncbi.nlm.nih.gov/8381954 8381954]| [https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/3257757 3257757]|[https://pubmed.ncbi.nlm.nih.gov/6792413 6792413]|[https://pubmed.ncbi.nlm.nih.gov/25039359 25039359] <br> | ||
'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789 | '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789 <br> | ||
'''term_xref''' : GTC:G80062GG |GlycoEpitope:EP0037|CID | '''term_xref''' : GTC:G80062GG |GlycoEpitope:EP0037|CID 91825690|CHEBI:85789 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 567: | Line 567: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G80062GG G80062GG] <br> | ||
'''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]] <br> | '''term_in_sentence''' : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]|268649|[https://pubmed.ncbi.nlm.nih.gov/23240079 23240079]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3040119 3040119]|268649|[https://pubmed.ncbi.nlm.nih.gov/23240079 23240079]|[https://pubmed.ncbi.nlm.nih.gov/28134301 28134301]|[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]|[https://pubmed.ncbi.nlm.nih.gov/1138893 1138893]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/10506200 10506200]|[https://pubmed.ncbi.nlm.nih.gov/8855242 8855242]|[https://pubmed.ncbi.nlm.nih.gov/1955453 1955453]|[https://pubmed.ncbi.nlm.nih.gov/1933935 1933935]|[https://pubmed.ncbi.nlm.nih.gov/3355161 3355161]|[https://pubmed.ncbi.nlm.nih.gov/6773959 6773959]|[https://pubmed.ncbi.nlm.nih.gov/14573676 14573676]|[https://pubmed.ncbi.nlm.nih.gov/29898878 29898878]|[https://pubmed.ncbi.nlm.nih.gov/10431785 10431785]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/11214737 11214737]|[https://pubmed.ncbi.nlm.nih.gov/7423202 7423202]|[https://pubmed.ncbi.nlm.nih.gov/389939 389939]|[https://pubmed.ncbi.nlm.nih.gov/3871816 3871816]|[https://pubmed.ncbi.nlm.nih.gov/6187373 6187373]|[https://pubmed.ncbi.nlm.nih.gov/16133832 16133832]|[https://pubmed.ncbi.nlm.nih.gov/469271 469271]|[https://pubmed.ncbi.nlm.nih.gov/3753492 3753492]|[https://pubmed.ncbi.nlm.nih.gov/2695680 2695680]|[https://pubmed.ncbi.nlm.nih.gov/7037611 7037611]|[https://pubmed.ncbi.nlm.nih.gov/25703376 25703376]|[https://pubmed.ncbi.nlm.nih.gov/23798992 23798992]|[https://pubmed.ncbi.nlm.nih.gov/414913 414913]|[https://pubmed.ncbi.nlm.nih.gov/1868069 1868069]| [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243] <br> | ||
'''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br> | '''definition''' : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID: | '''term_xref''' : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86 <br> | ||
'''synonyms''' : Forssman antigen|Globopentosylceramide <br> | '''synonyms''' : Forssman antigen|Globopentosylceramide <br> | ||
'''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]] <br> | '''function''' : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:[https://pubmed.ncbi.nlm.nih.gov/3495590 3495590]] <br> | ||
Line 599: | Line 599: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]|[https://pubmed.ncbi.nlm.nih.gov/16880505 16880505]|[https://pubmed.ncbi.nlm.nih.gov/9089399 9089399]|[https://pubmed.ncbi.nlm.nih.gov/29789847 29789847]|[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]|[https://pubmed.ncbi.nlm.nih.gov/19556222 19556222]|[https://pubmed.ncbi.nlm.nih.gov/1660040 1660040]|[https://pubmed.ncbi.nlm.nih.gov/2420639 2420639]|[https://pubmed.ncbi.nlm.nih.gov/9076515 9076515]|[https://pubmed.ncbi.nlm.nih.gov/15926079 15926079]|[https://pubmed.ncbi.nlm.nih.gov/19555091 19555091]|[https://pubmed.ncbi.nlm.nih.gov/2541996 2541996]|[https://pubmed.ncbi.nlm.nih.gov/16211870 16211870]|[https://pubmed.ncbi.nlm.nih.gov/1336587 1336587]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/14967068 14967068]|[https://pubmed.ncbi.nlm.nih.gov/18923900 18923900]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/16941490 16941490]|[https://pubmed.ncbi.nlm.nih.gov/27070150 27070150]|[https://pubmed.ncbi.nlm.nih.gov/8305235 8305235]|[https://pubmed.ncbi.nlm.nih.gov/10602885 10602885]|[https://pubmed.ncbi.nlm.nih.gov/2645049 2645049]|[https://pubmed.ncbi.nlm.nih.gov/7993838 7993838]|[https://pubmed.ncbi.nlm.nih.gov/10537341 10537341]|[https://pubmed.ncbi.nlm.nih.gov/3002616 3002616]|[https://pubmed.ncbi.nlm.nih.gov/8336147 8336147]|[https://pubmed.ncbi.nlm.nih.gov/15447995 15447995]|[https://pubmed.ncbi.nlm.nih.gov/8905401 8905401]|[https://pubmed.ncbi.nlm.nih.gov/11714535 11714535]|[https://pubmed.ncbi.nlm.nih.gov/9260862 9260862]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/3315641 3315641]|[https://pubmed.ncbi.nlm.nih.gov/8076384 8076384]|[https://pubmed.ncbi.nlm.nih.gov/2317201 2317201]|[https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]|[https://pubmed.ncbi.nlm.nih.gov/6403518 6403518] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6619101 6619101]|[https://pubmed.ncbi.nlm.nih.gov/16880505 16880505]|[https://pubmed.ncbi.nlm.nih.gov/9089399 9089399]|[https://pubmed.ncbi.nlm.nih.gov/29789847 29789847]|[https://pubmed.ncbi.nlm.nih.gov/8068725 8068725]|[https://pubmed.ncbi.nlm.nih.gov/19556222 19556222]|[https://pubmed.ncbi.nlm.nih.gov/1660040 1660040]|[https://pubmed.ncbi.nlm.nih.gov/2420639 2420639]|[https://pubmed.ncbi.nlm.nih.gov/9076515 9076515]|[https://pubmed.ncbi.nlm.nih.gov/15926079 15926079]|[https://pubmed.ncbi.nlm.nih.gov/19555091 19555091]|[https://pubmed.ncbi.nlm.nih.gov/2541996 2541996]|[https://pubmed.ncbi.nlm.nih.gov/16211870 16211870]|[https://pubmed.ncbi.nlm.nih.gov/1336587 1336587]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/14967068 14967068]|[https://pubmed.ncbi.nlm.nih.gov/18923900 18923900]|[https://pubmed.ncbi.nlm.nih.gov/30021910 30021910]|[https://pubmed.ncbi.nlm.nih.gov/16941490 16941490]|[https://pubmed.ncbi.nlm.nih.gov/27070150 27070150]|[https://pubmed.ncbi.nlm.nih.gov/8305235 8305235]|[https://pubmed.ncbi.nlm.nih.gov/10602885 10602885]|[https://pubmed.ncbi.nlm.nih.gov/2645049 2645049]|[https://pubmed.ncbi.nlm.nih.gov/7993838 7993838]|[https://pubmed.ncbi.nlm.nih.gov/10537341 10537341]|[https://pubmed.ncbi.nlm.nih.gov/3002616 3002616]|[https://pubmed.ncbi.nlm.nih.gov/8336147 8336147]|[https://pubmed.ncbi.nlm.nih.gov/15447995 15447995]|[https://pubmed.ncbi.nlm.nih.gov/8905401 8905401]|[https://pubmed.ncbi.nlm.nih.gov/11714535 11714535]|[https://pubmed.ncbi.nlm.nih.gov/9260862 9260862]|[https://pubmed.ncbi.nlm.nih.gov/32228455 32228455]|[https://pubmed.ncbi.nlm.nih.gov/3315641 3315641]|[https://pubmed.ncbi.nlm.nih.gov/8076384 8076384]|[https://pubmed.ncbi.nlm.nih.gov/2317201 2317201]|[https://pubmed.ncbi.nlm.nih.gov/3680254 3680254]|[https://pubmed.ncbi.nlm.nih.gov/6403518 6403518] <br> | ||
'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br> | '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686] <br> | ||
'''term_xref''' : GTC:G91532KA |GlycoEpitope:EP0049|CID: | '''term_xref''' : GTC:G91532KA |GlycoEpitope:EP0049|CID: 53356699|CHEBI:62686 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 611: | Line 611: | ||
'''glycan_dictionary_accession''' : GSD000072 <br> | '''glycan_dictionary_accession''' : GSD000072 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID: | '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932] <br> | ||
'''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br> | '''definition''' : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
Line 641: | Line 641: | ||
'''glycan_dictionary_accession''' : GSD000074 <br> | '''glycan_dictionary_accession''' : GSD000074 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID: | '''term_in_sentence''' : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br> | ||
'''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br> | '''definition''' : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
Line 659: | Line 659: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/28151933 28151933]|[https://pubmed.ncbi.nlm.nih.gov/19545571 19545571]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16403022 16403022]|[https://pubmed.ncbi.nlm.nih.gov/28151933 28151933]|[https://pubmed.ncbi.nlm.nih.gov/19545571 19545571]|[https://pubmed.ncbi.nlm.nih.gov/22448293 22448293] <br> | ||
'''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br> | '''definition''' : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID: | '''term_xref''' : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID: 52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594 <br> | ||
'''synonyms''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br> | '''synonyms''' : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1 <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 672: | Line 672: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br> | '''term_in_sentence''' : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858] [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18214858 18214858]|[https://pubmed.ncbi.nlm.nih.gov/31141660 31141660]|[https://pubmed.ncbi.nlm.nih.gov/26869352 26869352]|[https://pubmed.ncbi.nlm.nih.gov/29790113 29790113]|[https://pubmed.ncbi.nlm.nih.gov/31931062 31931062] <br> | ||
'''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br> | '''definition''' : The fucose from GDP-fucose is transferred to N-linked glycans. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
Line 687: | Line 687: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]] <br> | '''term_in_sentence''' : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2513186 2513186]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/15051952 15051952]|[https://pubmed.ncbi.nlm.nih.gov/12943224 12943224] <br> | ||
'''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br> | '''definition''' : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : appears in human alpha-fetoprotein (AFP).[PMID: | '''function''' : appears in human alpha-fetoprotein (AFP).[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] <br> | ||
'''disease_associations''' : neoplastic diseases of the liver[PMID: | '''disease_associations''' : neoplastic diseases of the liver[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]] |hepatocellular carcinoma[PMID: [https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]]. <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453068/ Chapter 43]<br> | '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453068/ Chapter 43]<br> | ||
Line 702: | Line 702: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67988RO G67988RO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67988RO G67988RO] <br> | ||
'''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:[https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]] <br> | '''term_in_sentence''' : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:[https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/33360824 33360824]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/25582508 25582508]|[https://pubmed.ncbi.nlm.nih.gov/2824515 2824515]|[https://pubmed.ncbi.nlm.nih.gov/4027258 4027258]|[https://pubmed.ncbi.nlm.nih.gov/32854306 32854306]|[https://pubmed.ncbi.nlm.nih.gov/32868283 32868283]|[https://pubmed.ncbi.nlm.nih.gov/31319156 31319156]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27367163 27367163]|[https://pubmed.ncbi.nlm.nih.gov/2564247 2564247]|[https://pubmed.ncbi.nlm.nih.gov/27727434 27727434]|[https://pubmed.ncbi.nlm.nih.gov/10216186 10216186]| [https://pubmed.ncbi.nlm.nih.gov/10460829 10460829]|[https://pubmed.ncbi.nlm.nih.gov/24992926 24992926]|[https://pubmed.ncbi.nlm.nih.gov/23590301 23590301]|[https://pubmed.ncbi.nlm.nih.gov/15702404 15702404]|[https://pubmed.ncbi.nlm.nih.gov/1854798 1854798]|[https://pubmed.ncbi.nlm.nih.gov/14761135 14761135]|[https://pubmed.ncbi.nlm.nih.gov/3600200 3600200]|[https://pubmed.ncbi.nlm.nih.gov/8603914 8603914]|[https://pubmed.ncbi.nlm.nih.gov/8601603 8601603]|[https://pubmed.ncbi.nlm.nih.gov/1965141 1965141]|[https://pubmed.ncbi.nlm.nih.gov/17400502 17400502]|[https://pubmed.ncbi.nlm.nih.gov/3840690 3840690]|[https://pubmed.ncbi.nlm.nih.gov/15959771 15959771]|[https://pubmed.ncbi.nlm.nih.gov/7930586 7930586]|[https://pubmed.ncbi.nlm.nih.gov/7721812 7721812]|[https://pubmed.ncbi.nlm.nih.gov/17095952 17095952]|[https://pubmed.ncbi.nlm.nih.gov/2500499 2500499]|[https://pubmed.ncbi.nlm.nih.gov/3815386 3815386]|[https://pubmed.ncbi.nlm.nih.gov/8842706 8842706]|[https://pubmed.ncbi.nlm.nih.gov/10746023 10746023]|[https://pubmed.ncbi.nlm.nih.gov/3928791 3928791]|[https://pubmed.ncbi.nlm.nih.gov/3782065 3782065]|[https://pubmed.ncbi.nlm.nih.gov/6440894 6440894] <br> | ||
'''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br> | '''definition''' : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314] <br> | ||
'''term_xref''' : GlycoEpitope:EP0113|GTC:G67988RO|CID: | '''term_xref''' : GlycoEpitope:EP0113|GTC:G67988RO|CID: 5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 731: | Line 731: | ||
'''glycan_dictionary_accession''' : GSD000080 <br> | '''glycan_dictionary_accession''' : GSD000080 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G33532XU G33532XU] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G33532XU G33532XU] <br> | ||
'''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: | '''term_in_sentence''' : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: [https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15704108 15704108]|[https://pubmed.ncbi.nlm.nih.gov/11278988 11278988]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/15704108 15704108]|[https://pubmed.ncbi.nlm.nih.gov/11278988 11278988]|[https://pubmed.ncbi.nlm.nih.gov/12084983 12084983]|[https://pubmed.ncbi.nlm.nih.gov/7509790 7509790] <br> | ||
'''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID: | '''definition''' : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID: 91857945] <br> | ||
'''term_xref''' : GlycoEpitope:EP0097|GTC:G33532XU|CID: | '''term_xref''' : GlycoEpitope:EP0097|GTC:G33532XU|CID: 91857945|CHEBI:149360 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 747: | Line 747: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99053DY G99053DY] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99053DY G99053DY] <br> | ||
'''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]] <br> | '''term_in_sentence''' : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]|[https://pubmed.ncbi.nlm.nih.gov/31540393 31540393]|[https://pubmed.ncbi.nlm.nih.gov/31140679 31140679]|[https://pubmed.ncbi.nlm.nih.gov/3028540 3028540]|[https://pubmed.ncbi.nlm.nih.gov/3674263 3674263]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12401210 12401210]|[https://pubmed.ncbi.nlm.nih.gov/25839135 25839135]|[https://pubmed.ncbi.nlm.nih.gov/31540393 31540393]|[https://pubmed.ncbi.nlm.nih.gov/31140679 31140679]|[https://pubmed.ncbi.nlm.nih.gov/3028540 3028540]|[https://pubmed.ncbi.nlm.nih.gov/3674263 3674263]|[https://pubmed.ncbi.nlm.nih.gov/31339142 31339142]|[https://pubmed.ncbi.nlm.nih.gov/30026902 30026902]|[https://pubmed.ncbi.nlm.nih.gov/10721708 10721708]|[https://pubmed.ncbi.nlm.nih.gov/30671362 30671362]|[https://pubmed.ncbi.nlm.nih.gov/26176557 26176557]|[https://pubmed.ncbi.nlm.nih.gov/25039255 25039255]|[https://pubmed.ncbi.nlm.nih.gov/24044869 24044869]|[https://pubmed.ncbi.nlm.nih.gov/32567311 32567311]|[https://pubmed.ncbi.nlm.nih.gov/27857717 27857717]|[https://pubmed.ncbi.nlm.nih.gov/21491978 21491978]|[https://pubmed.ncbi.nlm.nih.gov/24910250 24910250]|[https://pubmed.ncbi.nlm.nih.gov/29077212 29077212]|[https://pubmed.ncbi.nlm.nih.gov/8014006 8014006]|[https://pubmed.ncbi.nlm.nih.gov/27107335 27107335]|[https://pubmed.ncbi.nlm.nih.gov/32679486 32679486]|[https://pubmed.ncbi.nlm.nih.gov/1747956 1747956]|[https://pubmed.ncbi.nlm.nih.gov/8679447 8679447]|[https://pubmed.ncbi.nlm.nih.gov/28352526 28352526]|[https://pubmed.ncbi.nlm.nih.gov/11341836 11341836]|[https://pubmed.ncbi.nlm.nih.gov/10837462 10837462]| [https://pubmed.ncbi.nlm.nih.gov/7960243 7960243]|[https://pubmed.ncbi.nlm.nih.gov/16158941 16158941]|[https://pubmed.ncbi.nlm.nih.gov/3297853 3297853]|[https://pubmed.ncbi.nlm.nih.gov/2431136 2431136]|[https://pubmed.ncbi.nlm.nih.gov/21734356 21734356]|[https://pubmed.ncbi.nlm.nih.gov/8625206 8625206]|[https://pubmed.ncbi.nlm.nih.gov/30732055 30732055]|[https://pubmed.ncbi.nlm.nih.gov/12716912 12716912]|[https://pubmed.ncbi.nlm.nih.gov/20128040 20128040]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447]|[https://pubmed.ncbi.nlm.nih.gov/14659673 14659673] <br> | ||
'''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br> | '''definition''' : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:[https://pubmed.ncbi.nlm.nih.gov/53239691 53239691]|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12<br> | '''term_xref''' : GlycoMotif:GGM.000076|GTC:G99053DY|CID:[https://pubmed.ncbi.nlm.nih.gov/53239691 53239691]|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12<br> | ||
Line 764: | Line 764: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/5652802 5652802]|[https://pubmed.ncbi.nlm.nih.gov/25345088 25345088]|[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]|[https://pubmed.ncbi.nlm.nih.gov/29361370 29361370]|[https://pubmed.ncbi.nlm.nih.gov/31234327 31234327]|[https://pubmed.ncbi.nlm.nih.gov/30264864 30264864]|[https://pubmed.ncbi.nlm.nih.gov/25250137 25250137]|[https://pubmed.ncbi.nlm.nih.gov/7528216 7528216]|[https://pubmed.ncbi.nlm.nih.gov/31669751 31669751]|[https://pubmed.ncbi.nlm.nih.gov/20684311 20684311]|[https://pubmed.ncbi.nlm.nih.gov/16306603 16306603]|[https://pubmed.ncbi.nlm.nih.gov/10420586 10420586]|[https://pubmed.ncbi.nlm.nih.gov/7766692 7766692]|[https://pubmed.ncbi.nlm.nih.gov/31614613 31614613]|[https://pubmed.ncbi.nlm.nih.gov/26384672 26384672]|[https://pubmed.ncbi.nlm.nih.gov/31613991 31613991]|[https://pubmed.ncbi.nlm.nih.gov/19210136 19210136]|[https://pubmed.ncbi.nlm.nih.gov/8926633 8926633]|[https://pubmed.ncbi.nlm.nih.gov/29696051 29696051]|[https://pubmed.ncbi.nlm.nih.gov/32300455 32300455]|[https://pubmed.ncbi.nlm.nih.gov/7513313 7513313]|[https://pubmed.ncbi.nlm.nih.gov/26674302 26674302]|[https://pubmed.ncbi.nlm.nih.gov/20336376 20336376]|[https://pubmed.ncbi.nlm.nih.gov/24259734 24259734]|[https://pubmed.ncbi.nlm.nih.gov/31704237 31704237]|[https://pubmed.ncbi.nlm.nih.gov/21067946 21067946]|[https://pubmed.ncbi.nlm.nih.gov/30516933 30516933]|[https://pubmed.ncbi.nlm.nih.gov/27979707 27979707]|[https://pubmed.ncbi.nlm.nih.gov/26345314 26345314]|[https://pubmed.ncbi.nlm.nih.gov/30516941 30516941]|[https://pubmed.ncbi.nlm.nih.gov/31849452 31849452]|[https://pubmed.ncbi.nlm.nih.gov/27789132 27789132]|[https://pubmed.ncbi.nlm.nih.gov/30218706 30218706]|[https://pubmed.ncbi.nlm.nih.gov/29388611 29388611]|[https://pubmed.ncbi.nlm.nih.gov/20177787 20177787] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/5652802 5652802]|[https://pubmed.ncbi.nlm.nih.gov/25345088 25345088]|[https://pubmed.ncbi.nlm.nih.gov/31791361 31791361]|[https://pubmed.ncbi.nlm.nih.gov/29361370 29361370]|[https://pubmed.ncbi.nlm.nih.gov/31234327 31234327]|[https://pubmed.ncbi.nlm.nih.gov/30264864 30264864]|[https://pubmed.ncbi.nlm.nih.gov/25250137 25250137]|[https://pubmed.ncbi.nlm.nih.gov/7528216 7528216]|[https://pubmed.ncbi.nlm.nih.gov/31669751 31669751]|[https://pubmed.ncbi.nlm.nih.gov/20684311 20684311]|[https://pubmed.ncbi.nlm.nih.gov/16306603 16306603]|[https://pubmed.ncbi.nlm.nih.gov/10420586 10420586]|[https://pubmed.ncbi.nlm.nih.gov/7766692 7766692]|[https://pubmed.ncbi.nlm.nih.gov/31614613 31614613]|[https://pubmed.ncbi.nlm.nih.gov/26384672 26384672]|[https://pubmed.ncbi.nlm.nih.gov/31613991 31613991]|[https://pubmed.ncbi.nlm.nih.gov/19210136 19210136]|[https://pubmed.ncbi.nlm.nih.gov/8926633 8926633]|[https://pubmed.ncbi.nlm.nih.gov/29696051 29696051]|[https://pubmed.ncbi.nlm.nih.gov/32300455 32300455]|[https://pubmed.ncbi.nlm.nih.gov/7513313 7513313]|[https://pubmed.ncbi.nlm.nih.gov/26674302 26674302]|[https://pubmed.ncbi.nlm.nih.gov/20336376 20336376]|[https://pubmed.ncbi.nlm.nih.gov/24259734 24259734]|[https://pubmed.ncbi.nlm.nih.gov/31704237 31704237]|[https://pubmed.ncbi.nlm.nih.gov/21067946 21067946]|[https://pubmed.ncbi.nlm.nih.gov/30516933 30516933]|[https://pubmed.ncbi.nlm.nih.gov/27979707 27979707]|[https://pubmed.ncbi.nlm.nih.gov/26345314 26345314]|[https://pubmed.ncbi.nlm.nih.gov/30516941 30516941]|[https://pubmed.ncbi.nlm.nih.gov/31849452 31849452]|[https://pubmed.ncbi.nlm.nih.gov/27789132 27789132]|[https://pubmed.ncbi.nlm.nih.gov/30218706 30218706]|[https://pubmed.ncbi.nlm.nih.gov/29388611 29388611]|[https://pubmed.ncbi.nlm.nih.gov/20177787 20177787] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID: | '''term_xref''' : GlycoMotif:GGM.000105|GTC:G81983KG|CID: 91859783|KEGG:G00126 <br> | ||
'''synonyms''' : GD1c <br> | '''synonyms''' : GD1c <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 777: | Line 777: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G46677TE G46677TE] | [https://glygen.org/glycan/G45714BQ G45714BQ]<br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G46677TE G46677TE] | [https://glygen.org/glycan/G45714BQ G45714BQ]<br> | ||
'''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]] <br> | '''term_in_sentence''' : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]|[https://pubmed.ncbi.nlm.nih.gov/26860251 26860251]|[https://pubmed.ncbi.nlm.nih.gov/21930390 21930390]|[https://pubmed.ncbi.nlm.nih.gov/32906699 32906699]|[https://pubmed.ncbi.nlm.nih.gov/26054879 26054879]|[https://pubmed.ncbi.nlm.nih.gov/29951721 29951721]|[https://pubmed.ncbi.nlm.nih.gov/11745410 11745410]|[https://pubmed.ncbi.nlm.nih.gov/17653976 17653976]|[https://pubmed.ncbi.nlm.nih.gov/26119566 26119566]|[https://pubmed.ncbi.nlm.nih.gov/21554929 21554929]|[https://pubmed.ncbi.nlm.nih.gov/18435913 18435913]|[https://pubmed.ncbi.nlm.nih.gov/15342262 15342262]|[https://pubmed.ncbi.nlm.nih.gov/26865725 26865725]|[https://pubmed.ncbi.nlm.nih.gov/21151139 21151139]|[https://pubmed.ncbi.nlm.nih.gov/15716397 15716397]|[https://pubmed.ncbi.nlm.nih.gov/21492147 21492147]|[https://pubmed.ncbi.nlm.nih.gov/16942752 16942752]|[https://pubmed.ncbi.nlm.nih.gov/26973195 26973195]|[https://pubmed.ncbi.nlm.nih.gov/24449473 24449473]|[https://pubmed.ncbi.nlm.nih.gov/14999485 14999485]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20589721 20589721]|[https://pubmed.ncbi.nlm.nih.gov/10521808 10521808]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28899916 28899916]|[https://pubmed.ncbi.nlm.nih.gov/26860251 26860251]|[https://pubmed.ncbi.nlm.nih.gov/21930390 21930390]|[https://pubmed.ncbi.nlm.nih.gov/32906699 32906699]|[https://pubmed.ncbi.nlm.nih.gov/26054879 26054879]|[https://pubmed.ncbi.nlm.nih.gov/29951721 29951721]|[https://pubmed.ncbi.nlm.nih.gov/11745410 11745410]|[https://pubmed.ncbi.nlm.nih.gov/17653976 17653976]|[https://pubmed.ncbi.nlm.nih.gov/26119566 26119566]|[https://pubmed.ncbi.nlm.nih.gov/21554929 21554929]|[https://pubmed.ncbi.nlm.nih.gov/18435913 18435913]|[https://pubmed.ncbi.nlm.nih.gov/15342262 15342262]|[https://pubmed.ncbi.nlm.nih.gov/26865725 26865725]|[https://pubmed.ncbi.nlm.nih.gov/21151139 21151139]|[https://pubmed.ncbi.nlm.nih.gov/15716397 15716397]|[https://pubmed.ncbi.nlm.nih.gov/21492147 21492147]|[https://pubmed.ncbi.nlm.nih.gov/16942752 16942752]|[https://pubmed.ncbi.nlm.nih.gov/26973195 26973195]|[https://pubmed.ncbi.nlm.nih.gov/24449473 24449473]|[https://pubmed.ncbi.nlm.nih.gov/14999485 14999485]|[https://pubmed.ncbi.nlm.nih.gov/22735313 22735313]|[https://pubmed.ncbi.nlm.nih.gov/20589721 20589721]|[https://pubmed.ncbi.nlm.nih.gov/10521808 10521808]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/7827024 7827024]|[https://pubmed.ncbi.nlm.nih.gov/16897174 16897174]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/17227759 17227759] <br> | ||
'''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br> | '''definition''' : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID: | '''term_xref''' : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111 <br> | ||
'''synonyms''' : GD1alpha <br> | '''synonyms''' : GD1alpha <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 793: | Line 793: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37184KW G37184KW] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G37184KW G37184KW] <br> | ||
'''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]] <br> | '''term_in_sentence''' : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27144558 27144558]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332]|[https://pubmed.ncbi.nlm.nih.gov/18625966 18625966]|[https://pubmed.ncbi.nlm.nih.gov/7945223 7945223]|[https://pubmed.ncbi.nlm.nih.gov/32518172 32518172]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/31837178 31837178]|[https://pubmed.ncbi.nlm.nih.gov/20594196 20594196]|[https://pubmed.ncbi.nlm.nih.gov/30985655 30985655]|[https://pubmed.ncbi.nlm.nih.gov/11511306 11511306]|[https://pubmed.ncbi.nlm.nih.gov/1742806 1742806]|[https://pubmed.ncbi.nlm.nih.gov/11123278 11123278]|[https://pubmed.ncbi.nlm.nih.gov/7685064 7685064]|[https://pubmed.ncbi.nlm.nih.gov/2709011 2709011]|[https://pubmed.ncbi.nlm.nih.gov/33279873 33279873]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125]|[https://pubmed.ncbi.nlm.nih.gov/9179156 9179156]|[https://pubmed.ncbi.nlm.nih.gov/17964572 17964572]|[https://pubmed.ncbi.nlm.nih.gov/8821498 8821498]|[https://pubmed.ncbi.nlm.nih.gov/32726962 32726962]|[https://pubmed.ncbi.nlm.nih.gov/26560950 26560950]|[https://pubmed.ncbi.nlm.nih.gov/2611779 2611779]|[https://pubmed.ncbi.nlm.nih.gov/10072058 10072058]|[https://pubmed.ncbi.nlm.nih.gov/20030259 20030259]|[https://pubmed.ncbi.nlm.nih.gov/16415013 16415013]|[https://pubmed.ncbi.nlm.nih.gov/10797556 10797556]|[https://pubmed.ncbi.nlm.nih.gov/11342695 11342695]|[https://pubmed.ncbi.nlm.nih.gov/8619520 8619520]|[https://pubmed.ncbi.nlm.nih.gov/21519903 21519903]|[https://pubmed.ncbi.nlm.nih.gov/16199892 16199892]|[https://pubmed.ncbi.nlm.nih.gov/23777091 23777091]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/10481046 10481046] <br> | ||
'''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br> | '''definition''' : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000108|GTC:G37184KW|CID: | '''term_xref''' : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 808: | Line 808: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02657AK G02657AK] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G02657AK G02657AK] <br> | ||
'''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: [https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]] <br> | '''term_in_sentence''' : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: [https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28154831 28154831]|[https://pubmed.ncbi.nlm.nih.gov/32002293 32002293]|[https://pubmed.ncbi.nlm.nih.gov/32733795 32733795]|[https://pubmed.ncbi.nlm.nih.gov/28145567 28145567]|[https://pubmed.ncbi.nlm.nih.gov/31500597 31500597]|[https://pubmed.ncbi.nlm.nih.gov/31903906 31903906]|[https://pubmed.ncbi.nlm.nih.gov/29180536 29180536]|[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]|[https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]|[https://pubmed.ncbi.nlm.nih.gov/30617136 30617136]|[https://pubmed.ncbi.nlm.nih.gov/25604432 25604432]|[https://pubmed.ncbi.nlm.nih.gov/30198960 30198960]|[https://pubmed.ncbi.nlm.nih.gov/31075227 31075227]|[https://pubmed.ncbi.nlm.nih.gov/31721713 31721713]|[https://pubmed.ncbi.nlm.nih.gov/30955398 30955398]|[https://pubmed.ncbi.nlm.nih.gov/32195035 32195035]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28154831 28154831]|[https://pubmed.ncbi.nlm.nih.gov/32002293 32002293]|[https://pubmed.ncbi.nlm.nih.gov/32733795 32733795]|[https://pubmed.ncbi.nlm.nih.gov/28145567 28145567]|[https://pubmed.ncbi.nlm.nih.gov/31500597 31500597]|[https://pubmed.ncbi.nlm.nih.gov/31903906 31903906]|[https://pubmed.ncbi.nlm.nih.gov/29180536 29180536]|[https://pubmed.ncbi.nlm.nih.gov/28415563 28415563]|[https://pubmed.ncbi.nlm.nih.gov/25440605 25440605]|[https://pubmed.ncbi.nlm.nih.gov/30617136 30617136]|[https://pubmed.ncbi.nlm.nih.gov/25604432 25604432]|[https://pubmed.ncbi.nlm.nih.gov/30198960 30198960]|[https://pubmed.ncbi.nlm.nih.gov/31075227 31075227]|[https://pubmed.ncbi.nlm.nih.gov/31721713 31721713]|[https://pubmed.ncbi.nlm.nih.gov/30955398 30955398]|[https://pubmed.ncbi.nlm.nih.gov/32195035 32195035]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]|[https://pubmed.ncbi.nlm.nih.gov/31015228 31015228]|[https://pubmed.ncbi.nlm.nih.gov/31653037 31653037]|[https://pubmed.ncbi.nlm.nih.gov/31016728 31016728]|[https://pubmed.ncbi.nlm.nih.gov/30670592 30670592]|[https://pubmed.ncbi.nlm.nih.gov/30613134 30613134]|[https://pubmed.ncbi.nlm.nih.gov/29221154 29221154]|[https://pubmed.ncbi.nlm.nih.gov/30027525 30027525]|[https://pubmed.ncbi.nlm.nih.gov/29442009 29442009]|[https://pubmed.ncbi.nlm.nih.gov/31762628 31762628]|[https://pubmed.ncbi.nlm.nih.gov/30485077 30485077]|[https://pubmed.ncbi.nlm.nih.gov/25642322 25642322]| [https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/29151270 29151270]|[https://pubmed.ncbi.nlm.nih.gov/24773917 24773917]|[https://pubmed.ncbi.nlm.nih.gov/30612272 30612272]|[https://pubmed.ncbi.nlm.nih.gov/27654028 27654028]|[https://pubmed.ncbi.nlm.nih.gov/26298772 26298772] <br> | ||
'''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br> | '''definition''' : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID: | '''term_xref''' : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 823: | Line 823: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98544DH G98544DH] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G98544DH G98544DH] <br> | ||
'''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: [https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]] <br> | '''term_in_sentence''' : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: [https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30245960 30245960]|[https://pubmed.ncbi.nlm.nih.gov/27591028 27591028]|[https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]|[https://pubmed.ncbi.nlm.nih.gov/29069780 29069780]|[https://pubmed.ncbi.nlm.nih.gov/12470841 12470841]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30245960 30245960]|[https://pubmed.ncbi.nlm.nih.gov/27591028 27591028]|[https://pubmed.ncbi.nlm.nih.gov/12531552 12531552]|[https://pubmed.ncbi.nlm.nih.gov/29069780 29069780]|[https://pubmed.ncbi.nlm.nih.gov/12470841 12470841]|[https://pubmed.ncbi.nlm.nih.gov/29436609 29436609]|[https://pubmed.ncbi.nlm.nih.gov/28295752 28295752]|[https://pubmed.ncbi.nlm.nih.gov/27304202 27304202]]|[https://pubmed.ncbi.nlm.nih.gov/31138648 31138648]|[https://pubmed.ncbi.nlm.nih.gov/27288875 27288875]|[https://pubmed.ncbi.nlm.nih.gov/30446565 30446565]|[https://pubmed.ncbi.nlm.nih.gov/8721669 8721669]|[https://pubmed.ncbi.nlm.nih.gov/3903474 3903474]|[https://pubmed.ncbi.nlm.nih.gov/16081368 16081368]|[https://pubmed.ncbi.nlm.nih.gov/32743804 32743804]|[https://pubmed.ncbi.nlm.nih.gov/24372645 24372645]|[https://pubmed.ncbi.nlm.nih.gov/26792897 26792897]|[https://pubmed.ncbi.nlm.nih.gov/20890432 20890432]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/20581115 20581115]|[https://pubmed.ncbi.nlm.nih.gov/11174200 11174200]|[https://pubmed.ncbi.nlm.nih.gov/16040804 16040804]|[https://pubmed.ncbi.nlm.nih.gov/23783008 23783008]|[https://pubmed.ncbi.nlm.nih.gov/17368571 17368571]|[https://pubmed.ncbi.nlm.nih.gov/11023989 11023989]|[https://pubmed.ncbi.nlm.nih.gov/12901230 12901230]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/7061953 7061953]|[https://pubmed.ncbi.nlm.nih.gov/2231782 2231782]|[https://pubmed.ncbi.nlm.nih.gov/19423750 19423750]|[https://pubmed.ncbi.nlm.nih.gov/22632091 22632091]|[https://pubmed.ncbi.nlm.nih.gov/18202973 18202973]|[https://pubmed.ncbi.nlm.nih.gov/6392333 6392333]|[https://pubmed.ncbi.nlm.nih.gov/15896784 15896784]|[https://pubmed.ncbi.nlm.nih.gov/8261439 8261439]|[https://pubmed.ncbi.nlm.nih.gov/20052288 20052288]|[https://pubmed.ncbi.nlm.nih.gov/12847141 12847141]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/12118012 12118012]|[https://pubmed.ncbi.nlm.nih.gov/19912988 19912988]|[https://pubmed.ncbi.nlm.nih.gov/22795094 22795094]|[https://pubmed.ncbi.nlm.nih.gov/18655184 18655184]|[https://pubmed.ncbi.nlm.nih.gov/17043769 17043769]|[https://pubmed.ncbi.nlm.nih.gov/21395555 21395555]|[https://pubmed.ncbi.nlm.nih.gov/2472199 2472199]|[https://pubmed.ncbi.nlm.nih.gov/19776077 19776077] <br> | ||
'''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br> | '''definition''' : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID: | '''term_xref''' : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 853: | Line 853: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00061MO G00061MO] <br> | ||
'''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]] <br> | '''term_in_sentence''' : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:[https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/28392398 28392398]|[https://pubmed.ncbi.nlm.nih.gov/25787850 25787850]|[https://pubmed.ncbi.nlm.nih.gov/23471986 23471986]|[https://pubmed.ncbi.nlm.nih.gov/2559078 2559078]|[https://pubmed.ncbi.nlm.nih.gov/32455599 32455599]|[https://pubmed.ncbi.nlm.nih.gov/2663859 2663859]|[https://pubmed.ncbi.nlm.nih.gov/32796033 32796033]|[https://pubmed.ncbi.nlm.nih.gov/3517161 3517161]|[https://pubmed.ncbi.nlm.nih.gov/20082214 20082214]|[https://pubmed.ncbi.nlm.nih.gov/30853699 30853699]|[https://pubmed.ncbi.nlm.nih.gov/15279935 15279935]|[https://pubmed.ncbi.nlm.nih.gov/26104834 26104834]|[https://pubmed.ncbi.nlm.nih.gov/20732996 20732996]|[https://pubmed.ncbi.nlm.nih.gov/30224239 30224239]|[https://pubmed.ncbi.nlm.nih.gov/31142708 31142708]|[https://pubmed.ncbi.nlm.nih.gov/30338271 30338271]|[https://pubmed.ncbi.nlm.nih.gov/25033755 25033755]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/7104376 7104376]|[https://pubmed.ncbi.nlm.nih.gov/29866658 29866658]|[https://pubmed.ncbi.nlm.nih.gov/24983355 24983355]|[https://pubmed.ncbi.nlm.nih.gov/6794884 6794884]|[https://pubmed.ncbi.nlm.nih.gov/31361021 31361021]|[https://pubmed.ncbi.nlm.nih.gov/21740983 21740983]|[https://pubmed.ncbi.nlm.nih.gov/33168837 33168837]|[https://pubmed.ncbi.nlm.nih.gov/31752441 31752441]|[https://pubmed.ncbi.nlm.nih.gov/28123520 28123520]|[https://pubmed.ncbi.nlm.nih.gov/29068380 29068380]|[https://pubmed.ncbi.nlm.nih.gov/24841197 24841197]|[https://pubmed.ncbi.nlm.nih.gov/27932383 27932383]|[https://pubmed.ncbi.nlm.nih.gov/28535204 28535204]|[https://pubmed.ncbi.nlm.nih.gov/31691795 31691795]|[https://pubmed.ncbi.nlm.nih.gov/27916888 27916888]|[https://pubmed.ncbi.nlm.nih.gov/27558838 27558838]|[https://pubmed.ncbi.nlm.nih.gov/10227680 10227680]|[https://pubmed.ncbi.nlm.nih.gov/26464281 26464281]|[https://pubmed.ncbi.nlm.nih.gov/22348006 22348006]|[https://pubmed.ncbi.nlm.nih.gov/22279060 22279060]|[https://pubmed.ncbi.nlm.nih.gov/25156739 25156739]|[https://pubmed.ncbi.nlm.nih.gov/32314902 32314902]|[https://pubmed.ncbi.nlm.nih.gov/22718629 22718629]|[https://pubmed.ncbi.nlm.nih.gov/23701631 23701631]|[https://pubmed.ncbi.nlm.nih.gov/23906628 23906628]|[https://pubmed.ncbi.nlm.nih.gov/8613382 8613382]|[https://pubmed.ncbi.nlm.nih.gov/23555772 23555772]|[https://pubmed.ncbi.nlm.nih.gov/20059899 20059899]|[https://pubmed.ncbi.nlm.nih.gov/7868240 7868240] <br> | ||
'''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br> | '''definition''' : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID: | '''term_xref''' : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID: 5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032<br> | ||
'''synonyms''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br> | '''synonyms''' : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 869: | Line 869: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00059MO G00059MO] <br> | ||
'''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br> | '''term_in_sentence''' : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:[https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/32127409 32127409]|[https://pubmed.ncbi.nlm.nih.gov/28674962 28674962]|[https://pubmed.ncbi.nlm.nih.gov/30875019 30875019]|[https://pubmed.ncbi.nlm.nih.gov/30413389 30413389]|[https://pubmed.ncbi.nlm.nih.gov/31778662 31778662]|[https://pubmed.ncbi.nlm.nih.gov/31101366 31101366]|[https://pubmed.ncbi.nlm.nih.gov/24335674 24335674]|[https://pubmed.ncbi.nlm.nih.gov/31241709 31241709]|[https://pubmed.ncbi.nlm.nih.gov/24158513 24158513]|[https://pubmed.ncbi.nlm.nih.gov/28947349 28947349]|[https://pubmed.ncbi.nlm.nih.gov/31566927 31566927]|[https://pubmed.ncbi.nlm.nih.gov/28672034 28672034]|[https://pubmed.ncbi.nlm.nih.gov/31939530 31939530]|[https://pubmed.ncbi.nlm.nih.gov/29530250 29530250]|[https://pubmed.ncbi.nlm.nih.gov/27851774 27851774]|[https://pubmed.ncbi.nlm.nih.gov/26426881 26426881]|[https://pubmed.ncbi.nlm.nih.gov/25031264 25031264]|[https://pubmed.ncbi.nlm.nih.gov/29982630 29982630]|[https://pubmed.ncbi.nlm.nih.gov/24496231 24496231]|[https://pubmed.ncbi.nlm.nih.gov/29983334 29983334]|[https://pubmed.ncbi.nlm.nih.gov/28756410 28756410]|[https://pubmed.ncbi.nlm.nih.gov/27190352 27190352]|[https://pubmed.ncbi.nlm.nih.gov/29274327 29274327]|[https://pubmed.ncbi.nlm.nih.gov/29099167 29099167]|[https://pubmed.ncbi.nlm.nih.gov/28402705 28402705]|[https://pubmed.ncbi.nlm.nih.gov/23680766 23680766]|[https://pubmed.ncbi.nlm.nih.gov/28625968 28625968]|[https://pubmed.ncbi.nlm.nih.gov/26960552 26960552]|[https://pubmed.ncbi.nlm.nih.gov/26797827 26797827]|[https://pubmed.ncbi.nlm.nih.gov/22742555 22742555]|[https://pubmed.ncbi.nlm.nih.gov/27756537 27756537]|[https://pubmed.ncbi.nlm.nih.gov/31630715 31630715]|[https://pubmed.ncbi.nlm.nih.gov/3827883 3827883]|[https://pubmed.ncbi.nlm.nih.gov/28384397 28384397]|[https://pubmed.ncbi.nlm.nih.gov/29523338 29523338]|[https://pubmed.ncbi.nlm.nih.gov/31010832 31010832]|[https://pubmed.ncbi.nlm.nih.gov/27195818 27195818]|[https://pubmed.ncbi.nlm.nih.gov/26661087 26661087]|[https://pubmed.ncbi.nlm.nih.gov/23093409 23093409]|[https://pubmed.ncbi.nlm.nih.gov/30879639 30879639]|[https://pubmed.ncbi.nlm.nih.gov/27081853 27081853]|[https://pubmed.ncbi.nlm.nih.gov/17409683 17409683]|[https://pubmed.ncbi.nlm.nih.gov/29921669 29921669]|[https://pubmed.ncbi.nlm.nih.gov/25575293 25575293]|[https://pubmed.ncbi.nlm.nih.gov/26291612 26291612]|[https://pubmed.ncbi.nlm.nih.gov/23146289 23146289]|[https://pubmed.ncbi.nlm.nih.gov/25857295 25857295]|[https://pubmed.ncbi.nlm.nih.gov/26070511 26070511] <br> | ||
'''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br> | '''definition''' : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID: | '''term_xref''' : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID: 5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27 <br> | ||
'''synonyms''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br> | '''synonyms''' : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 900: | Line 900: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G48558GR G48558GR] <br> | ||
'''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br> | '''term_in_sentence''' : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490] | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/18524657 18524657]|[https://pubmed.ncbi.nlm.nih.gov/31761138 31761138]|[https://pubmed.ncbi.nlm.nih.gov/36180805 36180805]|[https://pubmed.ncbi.nlm.nih.gov/29920238 29920238]|[https://pubmed.ncbi.nlm.nih.gov/33859490 33859490]|[https://pubmed.ncbi.nlm.nih.gov/31937438 31937438]|[https://pubmed.ncbi.nlm.nih.gov/25762012 25762012]|[https://pubmed.ncbi.nlm.nih.gov/25931034 25931034]|[https://pubmed.ncbi.nlm.nih.gov/31776384 31776384]|[https://pubmed.ncbi.nlm.nih.gov/32013258 32013258]|[https://pubmed.ncbi.nlm.nih.gov/30776097 30776097]|[https://pubmed.ncbi.nlm.nih.gov/31048748 31048748]|[https://pubmed.ncbi.nlm.nih.gov/31447771 31447771]|[https://pubmed.ncbi.nlm.nih.gov/30292198 30292198]|[https://pubmed.ncbi.nlm.nih.gov/28796418 28796418]|[https://pubmed.ncbi.nlm.nih.gov/27806275 27806275]|[https://pubmed.ncbi.nlm.nih.gov/21076871 21076871]|[https://pubmed.ncbi.nlm.nih.gov/27552916 27552916]|[https://pubmed.ncbi.nlm.nih.gov/17986147 17986147]|[https://pubmed.ncbi.nlm.nih.gov/26960162 26960162]|[https://pubmed.ncbi.nlm.nih.gov/27815022 27815022]|[https://pubmed.ncbi.nlm.nih.gov/25851126 25851126]|[https://pubmed.ncbi.nlm.nih.gov/32916822 32916822]|[https://pubmed.ncbi.nlm.nih.gov/11462671 11462671]|[https://pubmed.ncbi.nlm.nih.gov/28236574 28236574]|[https://pubmed.ncbi.nlm.nih.gov/15911874 15911874]|[https://pubmed.ncbi.nlm.nih.gov/28577204 28577204]|[https://pubmed.ncbi.nlm.nih.gov/28497346 28497346]|[https://pubmed.ncbi.nlm.nih.gov/1794005 1794005]|[https://pubmed.ncbi.nlm.nih.gov/31934908 31934908]|[https://pubmed.ncbi.nlm.nih.gov/30267299 30267299]|[https://pubmed.ncbi.nlm.nih.gov/16902585 16902585]|[https://pubmed.ncbi.nlm.nih.gov/29439846 29439846]|[https://pubmed.ncbi.nlm.nih.gov/32325905 32325905]|[https://pubmed.ncbi.nlm.nih.gov/29747823 29747823]|[https://pubmed.ncbi.nlm.nih.gov/27576485 27576485]|[https://pubmed.ncbi.nlm.nih.gov/26338710 26338710]|[https://pubmed.ncbi.nlm.nih.gov/27858734 27858734]|[https://pubmed.ncbi.nlm.nih.gov/24501414 24501414]|[https://pubmed.ncbi.nlm.nih.gov/26818965 26818965]|[https://pubmed.ncbi.nlm.nih.gov/26629687 26629687]|[https://pubmed.ncbi.nlm.nih.gov/26958633 26958633]|[https://pubmed.ncbi.nlm.nih.gov/1854596 1854596]|[https://pubmed.ncbi.nlm.nih.gov/32134593 32134593]|[https://pubmed.ncbi.nlm.nih.gov/32198666 32198666]|[https://pubmed.ncbi.nlm.nih.gov/6619101 6619101] <br> | ||
'''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br> | '''definition''' : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br> | '''term_xref''' : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110 <br> | ||
Line 917: | Line 917: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29618308 29618308]|[https://pubmed.ncbi.nlm.nih.gov/27491214 27491214]|[https://pubmed.ncbi.nlm.nih.gov/32867370 32867370]|[https://pubmed.ncbi.nlm.nih.gov/30030044 30030044]|[https://pubmed.ncbi.nlm.nih.gov/27499644 27499644]|[https://pubmed.ncbi.nlm.nih.gov/31097363 31097363]|[https://pubmed.ncbi.nlm.nih.gov/29100724 29100724]|[https://pubmed.ncbi.nlm.nih.gov/27402091 27402091]|[https://pubmed.ncbi.nlm.nih.gov/31852956 31852956]|[https://pubmed.ncbi.nlm.nih.gov/30389374 30389374]|[https://pubmed.ncbi.nlm.nih.gov/30988135 30988135]|[https://pubmed.ncbi.nlm.nih.gov/8786814 8786814]|[https://pubmed.ncbi.nlm.nih.gov/14533808 14533808]|[https://pubmed.ncbi.nlm.nih.gov/23370522 23370522]|[https://pubmed.ncbi.nlm.nih.gov/28192816 28192816]|[https://pubmed.ncbi.nlm.nih.gov/32692591 32692591]|[https://pubmed.ncbi.nlm.nih.gov/29106755 29106755]|[https://pubmed.ncbi.nlm.nih.gov/28833537 28833537]|[https://pubmed.ncbi.nlm.nih.gov/11339652 11339652]|[https://pubmed.ncbi.nlm.nih.gov/9728335 9728335]|[https://pubmed.ncbi.nlm.nih.gov/27270764 27270764]|[https://pubmed.ncbi.nlm.nih.gov/9714704 9714704]|[https://pubmed.ncbi.nlm.nih.gov/26175473 26175473]|[https://pubmed.ncbi.nlm.nih.gov/27018595 27018595]|[https://pubmed.ncbi.nlm.nih.gov/28615102 28615102]|[https://pubmed.ncbi.nlm.nih.gov/28974375 28974375]|[https://pubmed.ncbi.nlm.nih.gov/32951593 32951593]|[https://pubmed.ncbi.nlm.nih.gov/11462672 11462672]|[https://pubmed.ncbi.nlm.nih.gov/28955902 28955902]|[https://pubmed.ncbi.nlm.nih.gov/17192692 17192692]|[https://pubmed.ncbi.nlm.nih.gov/26538065 26538065]|[https://pubmed.ncbi.nlm.nih.gov/25421609 25421609]|[https://pubmed.ncbi.nlm.nih.gov/9572057 9572057]|[https://pubmed.ncbi.nlm.nih.gov/11596983 11596983]|[https://pubmed.ncbi.nlm.nih.gov/15264019 15264019]|[https://pubmed.ncbi.nlm.nih.gov/23236285 23236285]|[https://pubmed.ncbi.nlm.nih.gov/11596984 11596984]|[https://pubmed.ncbi.nlm.nih.gov/31261761 31261761]|[https://pubmed.ncbi.nlm.nih.gov/30113798 30113798]|[https://pubmed.ncbi.nlm.nih.gov/24391178 24391178]|[https://pubmed.ncbi.nlm.nih.gov/24309906 24309906]|[https://pubmed.ncbi.nlm.nih.gov/22224667 22224667]|[https://pubmed.ncbi.nlm.nih.gov/7980537 7980537]|[https://pubmed.ncbi.nlm.nih.gov/18272501 18272501]|[https://pubmed.ncbi.nlm.nih.gov/9006924 9006924]| <br> | ||
'''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br> | '''definition''' : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID: | '''term_xref''' : GlycoMotif:GGM.000095|GTC:G79389NT|CID: 45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 932: | Line 932: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|739008| <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29376491 29376491]|[https://pubmed.ncbi.nlm.nih.gov/29747813 29747813]|[https://pubmed.ncbi.nlm.nih.gov/25613425 25613425]|[https://pubmed.ncbi.nlm.nih.gov/30318083 30318083]|[https://pubmed.ncbi.nlm.nih.gov/31526872 31526872]|[https://pubmed.ncbi.nlm.nih.gov/31004109 31004109]|[https://pubmed.ncbi.nlm.nih.gov/28019668 28019668]|[https://pubmed.ncbi.nlm.nih.gov/26434718 26434718]|[https://pubmed.ncbi.nlm.nih.gov/27313500 27313500]|[https://pubmed.ncbi.nlm.nih.gov/27539856 27539856]|[https://pubmed.ncbi.nlm.nih.gov/30111401 30111401]|[https://pubmed.ncbi.nlm.nih.gov/28544772 28544772]|[https://pubmed.ncbi.nlm.nih.gov/29407985 29407985]|[https://pubmed.ncbi.nlm.nih.gov/19364317 19364317]|[https://pubmed.ncbi.nlm.nih.gov/30190430 30190430]|[https://pubmed.ncbi.nlm.nih.gov/31297734 31297734]|[https://pubmed.ncbi.nlm.nih.gov/30091781 30091781]|[https://pubmed.ncbi.nlm.nih.gov/26043887 26043887]|[https://pubmed.ncbi.nlm.nih.gov/32183071 32183071]|[https://pubmed.ncbi.nlm.nih.gov/30665141 30665141]|[https://pubmed.ncbi.nlm.nih.gov/27873002 27873002]|[https://pubmed.ncbi.nlm.nih.gov/25801320 25801320]|[https://pubmed.ncbi.nlm.nih.gov/30209782 30209782]|[https://pubmed.ncbi.nlm.nih.gov/32378734 32378734]|[https://pubmed.ncbi.nlm.nih.gov/23050851 23050851]|[https://pubmed.ncbi.nlm.nih.gov/22768242 22768242]|[https://pubmed.ncbi.nlm.nih.gov/14993837 14993837]|[https://pubmed.ncbi.nlm.nih.gov/24934090 24934090]|[https://pubmed.ncbi.nlm.nih.gov/17638075 17638075]|[https://pubmed.ncbi.nlm.nih.gov/21518140 21518140]|[https://pubmed.ncbi.nlm.nih.gov/26102277 26102277]|[https://pubmed.ncbi.nlm.nih.gov/19759399 19759399]|[https://pubmed.ncbi.nlm.nih.gov/24502144 24502144]|[https://pubmed.ncbi.nlm.nih.gov/25303960 25303960]|[https://pubmed.ncbi.nlm.nih.gov/23564406 23564406]|[https://pubmed.ncbi.nlm.nih.gov/16636105 16636105]|[https://pubmed.ncbi.nlm.nih.gov/16491123 16491123]|[https://pubmed.ncbi.nlm.nih.gov/11259118 11259118]|[https://pubmed.ncbi.nlm.nih.gov/15102521 15102521]|[https://pubmed.ncbi.nlm.nih.gov/12724312 12724312]|[https://pubmed.ncbi.nlm.nih.gov/24985965 24985965]|[https://pubmed.ncbi.nlm.nih.gov/8496625 8496625]|[https://pubmed.ncbi.nlm.nih.gov/25403557 25403557]|[https://pubmed.ncbi.nlm.nih.gov/15690123 15690123]|[https://pubmed.ncbi.nlm.nih.gov/15939439 15939439]|[https://pubmed.ncbi.nlm.nih.gov/25893133 25893133]|[https://pubmed.ncbi.nlm.nih.gov/23591593 23591593]|[https://pubmed.ncbi.nlm.nih.gov/20634908 20634908]|[https://pubmed.ncbi.nlm.nih.gov/2004380 2004380]|739008| <br> | ||
'''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br> | '''definition''' : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID: | '''term_xref''' : GlycoMotif:GGM.000090|GTC:G91237TK|CID: 5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br> | '''function''' : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844] <br> | ||
'''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35 | '''disease_associations''' : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35] <br> | ||
'''wikipedia''' : <br> | '''wikipedia''' : <br> | ||
'''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br> | '''essentials_of_glycobiology''' : [https://www.ncbi.nlm.nih.gov/books/NBK453032/ Chapter 37]<br> | ||
Line 946: | Line 946: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G30207PZ G30207PZ] <br> | ||
'''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br> | '''term_in_sentence''' : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:[https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/23999868 23999868]|[https://pubmed.ncbi.nlm.nih.gov/2332419 2332419]|[https://pubmed.ncbi.nlm.nih.gov/12091485 12091485]|[https://pubmed.ncbi.nlm.nih.gov/19542236 19542236]|[https://pubmed.ncbi.nlm.nih.gov/8407875 8407875]|[https://pubmed.ncbi.nlm.nih.gov/23320941 23320941]|[https://pubmed.ncbi.nlm.nih.gov/28808804 28808804]|[https://pubmed.ncbi.nlm.nih.gov/3621237 3621237]|[https://pubmed.ncbi.nlm.nih.gov/23203271 23203271]|[https://pubmed.ncbi.nlm.nih.gov/7057115 7057115]|[https://pubmed.ncbi.nlm.nih.gov/26362868 26362868]|[https://pubmed.ncbi.nlm.nih.gov/6170387 6170387]|[https://pubmed.ncbi.nlm.nih.gov/18034482 18034482]|[https://pubmed.ncbi.nlm.nih.gov/7076644 7076644]|[https://pubmed.ncbi.nlm.nih.gov/2391348 2391348]|[https://pubmed.ncbi.nlm.nih.gov/25464080 25464080]|[https://pubmed.ncbi.nlm.nih.gov/3701369 3701369]|[https://pubmed.ncbi.nlm.nih.gov/11217952 11217952]|[https://pubmed.ncbi.nlm.nih.gov/6201236 6201236]|[https://pubmed.ncbi.nlm.nih.gov/30744426 30744426]|[https://pubmed.ncbi.nlm.nih.gov/9388026 9388026]|[https://pubmed.ncbi.nlm.nih.gov/27177620 27177620]|[https://pubmed.ncbi.nlm.nih.gov/30246056 30246056]|[https://pubmed.ncbi.nlm.nih.gov/15979459 15979459]|[https://pubmed.ncbi.nlm.nih.gov/7586078 7586078]|[https://pubmed.ncbi.nlm.nih.gov/6779816 6779816]|[https://pubmed.ncbi.nlm.nih.gov/29402905 29402905]|[https://pubmed.ncbi.nlm.nih.gov/7335153 7335153]|[https://pubmed.ncbi.nlm.nih.gov/3306476 3306476]|[https://pubmed.ncbi.nlm.nih.gov/17499534 17499534]|[https://pubmed.ncbi.nlm.nih.gov/7074082 7074082]|[https://pubmed.ncbi.nlm.nih.gov/9668345 9668345]|[https://pubmed.ncbi.nlm.nih.gov/3701884 3701884]|[https://pubmed.ncbi.nlm.nih.gov/26862430 26862430]|[https://pubmed.ncbi.nlm.nih.gov/6831238 6831238]|[https://pubmed.ncbi.nlm.nih.gov/27311552 27311552]|[https://pubmed.ncbi.nlm.nih.gov/26831445 26831445]|[https://pubmed.ncbi.nlm.nih.gov/24417799 24417799]|[https://pubmed.ncbi.nlm.nih.gov/7097284 7097284]|[https://pubmed.ncbi.nlm.nih.gov/4169231 4169231]|[https://pubmed.ncbi.nlm.nih.gov/16854400 16854400]|[https://pubmed.ncbi.nlm.nih.gov/26483798 26483798] <br> | ||
'''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position | '''definition''' : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position | ||
[CHEBI:63155] <br> | [CHEBI:63155] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID: | '''term_xref''' : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110 <br> | ||
'''synonyms''' : Sialylated GalCer<br> | '''synonyms''' : Sialylated GalCer<br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 962: | Line 962: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G93805MV G93805MV] <br> | ||
'''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br> | '''term_in_sentence''' : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1606358 1606358]|[https://pubmed.ncbi.nlm.nih.gov/19053458 19053458]|[https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/4091974 4091974]|[https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]|[https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/11432974 11432974]| [https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]|[https://pubmed.ncbi.nlm.nih.gov/1879553 1879553]| [https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/8969459 8969459]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/1304332 1304332]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/10564776 10564776] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV<br> | '''term_xref''' : GlycoMotif:GGM.000118|GTC:G93805MV<br> | ||
Line 977: | Line 977: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G18625KA G18625KA] <br> | ||
'''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br> | '''term_in_sentence''' : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30798387 30798387]|[https://pubmed.ncbi.nlm.nih.gov/31186474 31186474]|[https://pubmed.ncbi.nlm.nih.gov/26704905 26704905]|[https://pubmed.ncbi.nlm.nih.gov/23677659 23677659]|[https://pubmed.ncbi.nlm.nih.gov/26984947 26984947]|[https://pubmed.ncbi.nlm.nih.gov/24184316 24184316]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/9819299 9819299]|[https://pubmed.ncbi.nlm.nih.gov/18514410 18514410]|[https://pubmed.ncbi.nlm.nih.gov/22189683 22189683]|[https://pubmed.ncbi.nlm.nih.gov/24859332 24859332] <br> | ||
'''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br> | '''definition''' : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID: | '''term_xref''' : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 1,007: | Line 1,007: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G99524KA G99524KA] <br> | ||
'''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]] <br> | '''term_in_sentence''' : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6640289 6640289]| [https://pubmed.ncbi.nlm.nih.gov/1695858 1695858]|[https://pubmed.ncbi.nlm.nih.gov/7798936 7798936]|[https://pubmed.ncbi.nlm.nih.gov/1729139 1729139]|[https://pubmed.ncbi.nlm.nih.gov/2468656 2468656]|[https://pubmed.ncbi.nlm.nih.gov/20368669 20368669]|[https://pubmed.ncbi.nlm.nih.gov/2723647 2723647]|[https://pubmed.ncbi.nlm.nih.gov/1814411 1814411]| [https://pubmed.ncbi.nlm.nih.gov/3064875 3064875]|[https://pubmed.ncbi.nlm.nih.gov/6085330 6085330]|[https://pubmed.ncbi.nlm.nih.gov/1613492 1613492]|[https://pubmed.ncbi.nlm.nih.gov/17883393 17883393]|[https://pubmed.ncbi.nlm.nih.gov/11831845 11831845]| [https://pubmed.ncbi.nlm.nih.gov/10775425 10775425]|[https://pubmed.ncbi.nlm.nih.gov/8219015 8219015]|[https://pubmed.ncbi.nlm.nih.gov/8804704 8804704]|[https://pubmed.ncbi.nlm.nih.gov/1384262 1384262]|[https://pubmed.ncbi.nlm.nih.gov/7066685 7066685]|[https://pubmed.ncbi.nlm.nih.gov/2299192 2299192]|[https://pubmed.ncbi.nlm.nih.gov/9613831 9613831]|[https://pubmed.ncbi.nlm.nih.gov/10350354 10350354]|[https://pubmed.ncbi.nlm.nih.gov/1304337 1304337]|[https://pubmed.ncbi.nlm.nih.gov/9153001 9153001]|[https://pubmed.ncbi.nlm.nih.gov/11959025 11959025]|[https://pubmed.ncbi.nlm.nih.gov/8474578 8474578]|[https://pubmed.ncbi.nlm.nih.gov/2299350 2299350]| [https://pubmed.ncbi.nlm.nih.gov/10564776 10564776]|[https://pubmed.ncbi.nlm.nih.gov/10699494 10699494]|[https://pubmed.ncbi.nlm.nih.gov/3942818 3942818]|[https://pubmed.ncbi.nlm.nih.gov/12031286 12031286]|[https://pubmed.ncbi.nlm.nih.gov/7361620 7361620] <br> | ||
'''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID: | '''definition''' : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID: 91860352] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID: | '''term_xref''' : GlycoMotif:GGM.000117|GTC:G99524KA|CID: 91860352|CHEBI:145645|KEGG:G00121 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 1,022: | Line 1,022: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G68110IF G68110IF] <br> | ||
'''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br> | '''term_in_sentence''' : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/12023422 12023422]|[https://pubmed.ncbi.nlm.nih.gov/32623212 32623212]|[https://pubmed.ncbi.nlm.nih.gov/26197476 26197476]|[https://pubmed.ncbi.nlm.nih.gov/9585812 9585812]|[https://pubmed.ncbi.nlm.nih.gov/29747820 29747820]|[https://pubmed.ncbi.nlm.nih.gov/23804237 23804237]|[https://pubmed.ncbi.nlm.nih.gov/11993188 11993188]|[https://pubmed.ncbi.nlm.nih.gov/31683059 31683059]|[https://pubmed.ncbi.nlm.nih.gov/19631994 19631994]|[https://pubmed.ncbi.nlm.nih.gov/9742882 9742882]|[https://pubmed.ncbi.nlm.nih.gov/29709941 29709941]|[https://pubmed.ncbi.nlm.nih.gov/8971119 8971119]|[https://pubmed.ncbi.nlm.nih.gov/8706663 8706663]|893404|[https://pubmed.ncbi.nlm.nih.gov/31829433 31829433]|[https://pubmed.ncbi.nlm.nih.gov/8910600 8910600]|[https://pubmed.ncbi.nlm.nih.gov/30600291 30600291]|[https://pubmed.ncbi.nlm.nih.gov/29319803 29319803]|[https://pubmed.ncbi.nlm.nih.gov/26176883 26176883]|[https://pubmed.ncbi.nlm.nih.gov/29063860 29063860]|[https://pubmed.ncbi.nlm.nih.gov/6766128 6766128]|[https://pubmed.ncbi.nlm.nih.gov/31602715 31602715]|[https://pubmed.ncbi.nlm.nih.gov/29808463 29808463]|[https://pubmed.ncbi.nlm.nih.gov/30711390 30711390]|[https://pubmed.ncbi.nlm.nih.gov/29847988 29847988]|[https://pubmed.ncbi.nlm.nih.gov/30116054 30116054]|[https://pubmed.ncbi.nlm.nih.gov/28187751 28187751] <br> | ||
'''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br> | '''definition''' : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215] <br> | ||
'''term_xref''' : CID: | '''term_xref''' : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Line 1,039: | Line 1,039: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7710562 7710562]|[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]|[https://pubmed.ncbi.nlm.nih.gov/10972137 10972137]|[https://pubmed.ncbi.nlm.nih.gov/9468624 9468624]|[https://pubmed.ncbi.nlm.nih.gov/9143254 9143254]|[https://pubmed.ncbi.nlm.nih.gov/8221098 8221098]|[https://pubmed.ncbi.nlm.nih.gov/9679279 9679279]|[https://pubmed.ncbi.nlm.nih.gov/11368158 11368158]|[https://pubmed.ncbi.nlm.nih.gov/11878808 11878808] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7710562 7710562]|[https://pubmed.ncbi.nlm.nih.gov/8082783 8082783]|[https://pubmed.ncbi.nlm.nih.gov/10972137 10972137]|[https://pubmed.ncbi.nlm.nih.gov/9468624 9468624]|[https://pubmed.ncbi.nlm.nih.gov/9143254 9143254]|[https://pubmed.ncbi.nlm.nih.gov/8221098 8221098]|[https://pubmed.ncbi.nlm.nih.gov/9679279 9679279]|[https://pubmed.ncbi.nlm.nih.gov/11368158 11368158]|[https://pubmed.ncbi.nlm.nih.gov/11878808 11878808] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID: | '''term_xref''' : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID: 91851751|CHEBI:156678|KEGG:G00128 <br> | ||
'''synonyms''' : GT1aa <br> | '''synonyms''' : GT1aa <br> | ||
'''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br> | '''function''' : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111] <br> |
Revision as of 21:31, 10 April 2023
GSD000031
term (main_entry) : Blood group A1 (Type 3)
glycan_dictionary_accession : GSD000031
glytoucan_accession : G44060QH
term_in_sentence : The structure is essentially a repetitive A epitope attached to type 2 chain and is hereby called type 3 chain A. [PMID:2579390]
publication : 2579390|19756298
definition : A branched amino heptasaccharide made up from two repeating (1→3)-linked N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl units that are in turn joined to an N-acetyl-β-D-glucosamine residue via a (1→4)-linkage.[CHEBI:85665]
term_xref : GTC:G44060QH|CHEBI:85665|CID:91825676|GlycoMotif:GGM.000040
synonyms : Blood group A1 (type 3)|Blood Group A1
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000032

term (main_entry) : Blood group A2 (A-associated H type 3)
glycan_dictionary_accession : GSD000032
glytoucan_accession : G62735WZ
term_in_sentence : The H NMR spectrum of the associated H antigen (type 3 chain H) was characterized by the unusual presence of three n-anomeric resonances ('CJ'.~ = 3-4 Hz) in addition to five resonances from @-anomeric protons ("J1:2 = 7-9 Hz).[PMID: 3944091] publication : 3944091|29000000|28658771
definition : A branched amino hexasaccharide in which an α-L-fucosyl-(1→2)-β-D-galactosyl-(1→3)-N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second α-L-fucosyl residue via a (1→2) linkage.[CHEBI:152543]
term_xref : CHEBI:152543|CID: 91852328|GlycoMotif:GGM.000041|GTC:G62735WZ
synonyms : Blood Group A2|Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb|Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc|Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1→3)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)]-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose|6-deoxy-alpha-L-galactopyranosyl-(1→2)-[6-deoxy-alpha-L-galactopyranosyl-(1→2)-beta-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1→3)]-beta-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-glucopyranose
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000033

term (main_entry) : Blood group B (Type 1)
glycan_dictionary_accession : GSD000033
glytoucan_accession : G31734OS
term_in_sentence : The minimal binding epitope was identified as the blood group H type 1 determinant (Fucα2Galβ3GlcNAc), while an optimal binding epitope was created by addition of the terminal α3-linked galactose or N-acetylgalactosamine of the blood group B type 1 determinant (Galα3(Fucα2)Galβ3GlcNAc) and the blood group A type 1 determinant (GalNAcα3(Fucα2)-Galβ3GlcNAc). [PMID: 19208633]
publication : 18701592|24749871|19387828|19208633|29562255
definition : α-D-Galp-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-β-D-GlcpNAc with β configuration at the anomeric carbon of the GlcNAc residue at the reducing end.[CHEBI:63242]
term_xref : GlycoMotif:GGM.000043|GTC:G31734OS|CID:56927779|CHEBI:63242
synonyms : blood group B type 1 tetrasaccharide
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000034
term (main_entry) : Blood group B (Type 2)
glycan_dictionary_accession : GSD000034
glytoucan_accession : G34881WK
term_in_sentence : The detection of a B type 2 determinant is the first chemical evidence for the presence of an autologous difucosyl blood group B type 2 antigen in human adenocarcinoma cells.[PMID: 2432062]
publication : 2432062|27196314|18701592
definition :
term_xref : GlycoMotif:GGM.000037|GTC:G34881WK|GlycoEpitope:EP0262
synonyms : blood group B type 2
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000035
term (main_entry) : Blood group B (Type 4)
glycan_dictionary_accession : GSD000035
glytoucan_accession : G25216QA
term_in_sentence : The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type-4 compound in A kidneys.[PMID:1390942]
publication : 1390942|1841684
definition :
term_xref : GlycoMotif:GGM.000087|GTC:G25216QA
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000036
term (main_entry) : Blood group H (Type 1)
glycan_dictionary_accession : GSD000036
glytoucan_accession : G00294TN
term_in_sentence : Blood group H type 1 [Fuc alpha (1,2)Gal beta (1,3)GlcNAc beta-->] is known as the precursor structure of the blood group determinant, Lewis b [Fuc alpha (1,2)Gal beta (1,3)(Fuc alpha (1,4))GlcNAc beta-->].[PMID:7718581]
publication : 7718581|6309836|19208633|27431816| 2432062|24219248|6352465|8499478|3348768|3718924
definition :
term_xref : GTC:G00294TN|GlycoMotif:GGM.000042|SugarBind_Ligand:153
synonyms : H type 1
function :
disease_associations : Gastroenteritis[SugarBind_Ligand:153]
wikipedia :
essentials_of_glycobiology :
GSD000037

term (main_entry) : Blood group H (Type 2)
glycan_dictionary_accession : GSD000037
glytoucan_accession : G70519XK
term_in_sentence : We have examined the immunohistochemical distribution of H Type 1 and of H Type 2 substances of the ABO blood group system in human submandibular gland using either of the two anti-H monoclonal antibodies MAb 1E3 and MAb 3A5. MAb 3A5 was specific for H Type 2, and MAb 1E3 reacted with each of H Type 1-H Type 4 artificial antigens.[PMID: 9405495]
publication : 9405495|8082855|6177241|3944092|21406562|2410664|8731502|6203846|2238560|
definition :
term_xref : GTC:G70519XK|GlycoMotif:GGM.000036
synonyms : Blood group H (type 2)|H type 2|H type 2 chain|H type 2 antigen|type 2 chain H|blood group H type II
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000038

term (main_entry) : Blood group H (Type 2) - Lewis y
glycan_dictionary_accession : GSD000038
glytoucan_accession : G00052MO
term_in_sentence : The fucosylated histo-blood group antigens H type 2 (blood group O, CD173) and Lewis Y (CD174) are expressed on CD34+ hematopoietic progenitors but absent on mature lymphocytes.[PMID: 11479278]
publication : 11479278
definition : A branched amino tetrasaccharide consisting of N-acetyl-β-D-glucosamine at the reducing end having an α-L-fucosyl residue attached at the 3-position and an α-L-fucosyl-(1→2)-β-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.[CHEBI:59045]
term_xref : GTC:G00052MO|GlycoEpitope:EP0018|CID:45266908|CHEBI:59045|GlycoMotif:GGM.000045
synonyms : Lewis y|Blood group H (type 2) (Ley)|Lewis b (Leb)|Lewis a|Lewis b (Lewis b)|Blood group H (type 2) - Lewis y|H-Ley|H-Le^y|Lewis Y|H-Ley|H-Le^y|Lewis Y
function : The expression of the fucosylated histo-blood group antigen CD174 in CD34+ hematopoietic progenitor cells and down-regulation of FUT1 in mature lymphocytes may be important factors influencing the homing process of hematopoietic stem cells to the bone marrow.[GlycoEpitope:EP0018]
disease_associations : AIDS/acquired immune deficiency syndrome[GlycoEpitope:EP0018]|cholangiocarcinoma[GlycoEpitope:EP0018]|hepatocellular carcinoma[GlycoEpitope:EP0018]|Inappropriate tissue distribution of Ley blood-group antigens was observed in CCs(cholangiocarcinomas) and, much less frequently, in HCCs(hepatocellular carcinomas).[GlycoEpitope:EP0018]|Ley determinant is highly expressed in human immunodeficiency virus (HIV)-infected T cell lines and in CD3+ peripheral mature T cells of patients with acquired immune deficiency syndrome (AIDS) or with AIDS-related complex (ARC).[GlycoEpitope:EP0018]
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000039
term (main_entry) : Blood group H (Type 4)
glycan_dictionary_accession : GSD000039
glytoucan_accession : G98465JN
term_in_sentence : In addition, the blood group H type 4 chain structure was present together with Le(a) and Le(b) compounds.[PMID:1841684]
publication : 11261842| 1841684|11101633|9405495
definition : An amino hexasaccharide consisting of α-L-fucose, β-D-galactose, N-acetyl-α-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues joined in sequence with (1→2)-, (1→3)-, (1→3)-, (1→4)- and (1→4)-linkages, respectively.[CHEBI:65245]
term_xref : GlycoMotif:GGM.000086|GTC:G98465JN|CID:10260428|SugarBind_Ligand:61|CHEBI:65245
synonyms :
function :
disease_associations : Pyelonephritis[SugarBind_Ligand:61]
wikipedia :
essentials_of_glycobiology :
GSD000040
term (main_entry) : C2-O-sLex
glycan_dictionary_accession : GSD000040
glytoucan_accession : G97345NY
term_in_sentence : PSGL-1 lacks 6-sulfo-sLex but contains sulfated tyrosine residues (Tyr-SO3)at positions 46, 48, and 51 and sLex in a core 2-based O-glycan (C2-O-sLex) on Thr at position 57.[PMID:12736247]
publication : 12736247|19267921|21283832|15596301|17072011
definition : A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit α-Neu5Ac-(2→3)-β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-D-GalNAc.[CHEBI:65192]
term_xref : GlycoMotif:GGM.000053|GTC:G97345NY|CID:91860725|KEGG:G10899|CHEBI:155160
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000041

term (main_entry) : Ceramide dihexosyl sulfate
glycan_dictionary_accession : GSD000041
glytoucan_accession : G04416BG
term_in_sentence : Although it has been reported that ceramide dihexosyl sulfate is present in human kidney, it is unlikely that it is present in equine kidney.[PMID:818074]
publication : 818074
definition : A sulfatide with two hexose moieties (glucose and galactose) has been isolated from human kidney (Martensson E, Acta Chem Scand 1963, 17, 1174). Equimolar amounts of ceramide, glucose, galactose, and sulfate are found in the molecule. The sulfate group is esterified, as in sulfatides, with carbon 3 of the galactose moiety. The linkage between galactose and glucose is identical to lactose (b-1-4). Its fatty acid composition is similar to that of sulfatides. [http://cyberlipid.gerli.com/description/complex-lipids/glycolipids/glycosphingolipids/sulfosphingolipids/]
term_xref : GTC:G04416BG|GlycoMotif:GGM.000065
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000043
term (main_entry) : Chondroitin sulfate
glycan_dictionary_accession : GSD000043
glytoucan_accession :
term_in_sentence : The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw material derived from different terrestrial or marine species of animals.[PMID: 31013685]
publication : 31013685|27526113|27194526|26980567|28847361|24413804|29891297|29600622|25129732|31317901|29181550|31250530|22265655|25756648|29402610|17928217|20236040|28091940|30824935|26572336|31207331|21110089|30599999|20399897|27226567|19388612|23186102|31494830|28982096|30241863|30295666|25366475|20521042|29456007|31304829|18661362|28576008|29494632|30016441|26906924|24861964|23774590|31887904|31339761| 12512856|26957048|29625000
definition : Any of a class of 10—60 kDa glycosaminoglycan sulfates, widely distributed in cartilage and other mammalian connective tissues.[CHEBI:37397]
term_xref : CHEBI:37397|CID:24766
synonyms : chondroitin polysulfate|chondroitin sulfate|chondroitin sulfates|chondroitin sulfuric acid|chondroitin sulphate|Chondroitinsulfate
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000044
term (main_entry) : cisGM1
glycan_dictionary_accession : GSD000044
glytoucan_accession : G03277YI
term_in_sentence : Macrophage ganglioside patterns dramatically increase in complexity when murine peritoneal macrophages are stimulated in vivo with the appearance of the sialidase-sensitive monosialoganglioside GM1b (cisGM1) as a major component.[PMID: 9455923]
publication : 9455923
definition : A member of the class of neuraminic acids that is neuraminic acid attached in sequence to β-D-galactopyranosyl, 2-acetamido-2-deoxy-β-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-gucoopyranose units by (2→3), (1→3), (1→4), and (1→4) glycosidic linkages, respectively. It corresponds to the carbohydrate portion of ganglioside GM1b.[CHEBI:145580]
term_xref : GlycoMotif:GGM.000100|GTC:G03277YI|CID:91850212|CHEBI:145580|GlycoEpitope:EP0048|SugarBind_Ligand:92|KEGG:G00125
synonyms : GM1b
function :
disease_associations : Influenza[SugarBind_Ligand:92]
wikipedia :
essentials_of_glycobiology : Chapter 23
GSD000045
term (main_entry) : Complex-type N-glycans
glycan_dictionary_accession : GSD000045
glytoucan_accession :
term_in_sentence : In this study, 32 new complex-type glycans are characterized containing the Le(x), Le(Y), and sialyl-Le(x) determinants, the bloodgroup A and H antigens, as well as the ALe(Y) determinant.[PMID:10988252
publication : 29902282|29212795|29343819|27705835|26745022|18399796|16825488|21964725|15864431|22890903|12417032|28039392|19426135|30253927|16794314|19806620|22975979|25931033|15201278|19129634|19129628|24032650|22530754|31021709|30973186|28091941|23115339|20829342|27304954|29090617|21802690|29725121|30471292|16581187|26098720|31080188|1930135|31888963|30844485|24014058|11129583
definition : Type of N-linked glycan in which at least two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.
term_xref :
synonyms :
function : Involved in protein stability.[PMID:12417032]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 17
GSD000046
term (main_entry) : Core 2
glycan_dictionary_accession : GSD000046
glytoucan_accession : G00033MO
term_in_sentence : To investigate the biological roles of core 2 O-glycans, we produced and characterized mice deficient in one or more of the three known glycosyltransferases that generate core 2 O-glycans (C2GnT1, C2GnT2, and C2GnT3).[PMID: 19349303]
publication : 19349303|30315106|23640779|26677400
definition : The trisaccharide β-D-Gal-(1→3)-[β-D-GlcNAc-(1→6)]-D-GalNAc with α configuration at the anomeric centre of the N-acetylglucosamine residue at the reducing end.[CHEBI:62158]
term_xref : GTC:G00033MO|CID: 52921656|CHEBI:62158
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000047
term (main_entry) : Core 3
glycan_dictionary_accession : GSD000047
glytoucan_accession : G00035MO
term_in_sentence : Mechanically, we revealed that mucin-type core 3 O-glycan was synthesized at the membrane-tethered MUC1 N terminus because of core 3 synthase expression in colon cancer cells.[PMID: 28745318]
publication : 28745318|27259834|27143302|
definition : An amino disaccharide comprising an N-acetyl-β-D-glucosamine residue linked (1→3) to an N-acetyl-β-D-galactosamine residue at the reducing end.[CHEBI:71344]
term_xref : GTC:G00035MO|CID:25061208|CHEBI:71344
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 9
GSD000048
term (main_entry) : Core 4
glycan_dictionary_accession : GSD000048
glytoucan_accession : G00037MO
term_in_sentence : The results confirm the predicted existence of a beta1,6GlcNAc-transferase that functions in both core 2 and core 4 O-glycan branch formation.[PMID: 9988682]
publication : 9988682|10747980|
definition : A branched amino trisaccharide comprising an N -acetyl-α-D-galactosamine residue at the reducing end, to which are (1→3)- and (1→6)-linked two N -acetyl-α-D-glucosamine residues.[CHEBI:71341]
term_xref : GTC:G00037MO| CID:25229562|CHEBI:71341
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 8
GSD000049

term (main_entry) : Core-fucosylated
glycan_dictionary_accession : GSD000049
glytoucan_accession : G78059CC
term_in_sentence : The approach was validated for selective capture and analysis of core fucosylated N-glycans present in complex glycan mixtures derived from mammalian serum IgG.[PMID:27678371]
publication : 27678371|26514868|15538974|24914453| 17049014|32078267|31268672|28674882|29956878|27798819|32044029|30962950|31548313|30907281|29090617|29571940|28800497|27629418|29733746|31623829|28768188|26897254|31451706|26514868]|29427759|28982386|26587313|30940702| 15538974|31249452|27282921|31229844|30445455|31325506|24732908|29209018|26965517|28609658| 24914453|25573275|17049014|19218400|27012207|27139574| 32078267|25861849|32561391|21374780|31669139|25732060|29408166|31268672|30472795|30614075|19003000|25664929
definition : Modification of the N-glycan core structure with fucose moiety attached at the innermost GlcNAc by FUT8 enzyme. Core Fuc is found on paucimannose, hybrid and complex type N-glycans. [https://doi.org/10.1016/bs.acr.2014.11.006].
term_xref : GTC:G78059CC|CID: 70679232|CHEBI:70967|CHEBI:156499
synonyms : Core Fuc|6-linked Fuc|Fuca6 to chitobiose core|a6-linked Fuc|a1-6 Fuc|Fuca6 to chitobiose core|Fuc a1-6 to chitobiose core|Fuca6 to internal GlcNAc|Fuc a1-6 to internal GlcNAc
function : Required for signaling through TCR [PMID: 29434598]|VGF, PDGFr, and EGFr and TGFbeta receptor dysregulation in Fut8 KO mice [PMID:17132494]|IgG-Fcg receptor interactions destabilized by core Fuc [PMID:29062024]
disease_associations : Emphysema|systemic lupus erythematosuslung cancer|autoimmunity|tumor metastasis
wikipedia :
essentials_of_glycobiology : Chapter 8
GSD000050
term (main_entry) : Core-fucosylated biantennary
glycan_dictionary_accession : GSD000050
glytoucan_accession : G78059CC
term_in_sentence : The IFN-alpha14c N-glycans were shown to exhibit core-fucosylated biantennary glycans , with about 10% carrying an additional alpha1,3-linked fucose unit at the antennae.[PMID:9654101]
publication : 9654101|15819890|28263871|26763099|22256781|23681398|25855029|10529240|26544759|8206921|33149259|8547276
definition : A biantennary glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc.
term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499
synonyms : core-fucosylated diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 8
GSD000051
term (main_entry) : Core-fucosylated biantennary complex-type
glycan_dictionary_accession : GSD000051
glytoucan_accession : G78059CC
term_in_sentence : The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.[PMID:10731668]
publication : 10731668
definition : A biantennary complex glycan with two GlcNAc branches linked to the core and fucosylation on the core GlcNAc.
term_xref : GTC:G78059CC|CID:70679232|CHEBI:70967|CHEBI:156499
synonyms : core fucosylated diantennary complex-type
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000052

term (main_entry) : Cyclic sialyl 6-sulfo Lewis x
glycan_dictionary_accession : GSD000052
glytoucan_accession : G11148DZ
term_in_sentence : Stimulation of the sialyl 6-sulfo Lewis X-positive colon cancer cell line with a calcium ionophore ionomycin markedly reduced sialyl 6-sulfo Lewis X and induced cyclic sialyl 6-sulfo Lewis X expression.[PMID:10728707]
publication : 10728707|31222115|9990070|23088960
definition :
term_xref : GlycoEpitope:EP0017|CID: 91858084|CHEBI:147484
synonyms :
function : The accumulated intracellular cyclic sialyl 6-sulfo Lex determinant may function as a dormant pool of selectin ligands.[GlycoEpitope:EP0017]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000053
term (main_entry) : Cytolipin R
glycan_dictionary_accession : GSD000053
glytoucan_accession : G57710SU
term_in_sentence : The reaction can be inhibited completely by pure cytolipin R showing that (a) immune hemolysis can be mediated through lipid determinants in the membrane, and (b) that cytolipin R determinants are present in the intact erythrocyte membrane and exposed on the surface.[PMID:4110375]
publication : 893368|4375678|51702|186204|4110375|5068000|24174198|6072378|389925|[https://pubmed.ncbi.nlm.nih.gov/7054174 7054174
definition : A ceramide tetrahexoside isolated from rat lymphosarcoma. The structure of cytolipin R to be N-acetylgalactosaminyl(beta1-->3)galactosyl(alpha1-->3) galactosyl(beta1-->4)glucosyl ceramide.[PMID:5068000]
term_xref : GlycoMotif:GGM.000083|GTC:G57710SU|CID:91855936|KEGG:G00392|CHEBI:152175|SugarBind_Ligand:17
synonyms :
function :
disease_associations : Actinomycosis[SugarBind_Ligand:17]
wikipedia :
essentials_of_glycobiology :
GSD000054
term (main_entry) : Dermatan sulfate
glycan_dictionary_accession : GSD000054
glytoucan_accession :
term_in_sentence : By utilizing sophisticated separation methods followed by compositional analysis, domain mapping, and tandem mass spectrometry coupled with analysis by a modified genetic algorithm approach, the structural motif for the decorin dermatan sulfate chain was determined.[PMID:29111696]
publication : 27526113]|29111696|29891297|26164146|30869126|7789716|8597249|12512856| 31250530| 17928217|12213784|27226567|31455633|28091940|19075609|31071403|15078125|18661328|20581662|17239765|15749837|2777747|20632047|8930750|7762784|31006321|26876822|1522290|131009|26986023|8161353|15315969|12543559|30637950|2525357|18156656|9692613|9200333|19661164|2299256|16075147|1126924|9774430|8537360|15563459|21077227|23275130|17137817|6447930|6209270
definition : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated β1→4-linked L-iduronyl-(α1→3)-N-acetyl-D-galactosamine units.[CHEBI:18376]
term_xref : CHEBI:18376|CID:32756
synonyms : beta-Heparin|Chondroitin sulfate B|Dermatan L-iduronate
function : Wound healing[Essentials of Glycobiology:Chapter 7]|maintain the structure of the dermis.[Essentials of Glycobiology:Chapter 41]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000055
term (main_entry) : Desialylated
glycan_dictionary_accession : GSD000055
glytoucan_accession :
term_in_sentence : Furthermore, we found no evidence for "desialylated" apoB100 glycans in any of the samples analyzed.[PMID:11588155]
publication : 30015642|26168491|29492899|31774586|32321401|23780974|7600681|18045697|1450583|4137057|28911304|27562992|29950245|31978220|2408573|8612720|10910970|27195066|1434544|22175031|24517196|29794068|30101537|18972200|1478792|4440781|21229239|30844664|31351722|31330845|1872910
definition : A glycan from which sialyl groups have been removed. [https://en.wiktionary.org/wiki/desialylated]
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000056
term (main_entry) : Desialylated tetrasaccharide
glycan_dictionary_accession : GSD000056
glytoucan_accession :
term_in_sentence : The structures of a desialylated tetrasaccharide , two monosialylated trisaccharides , and five other minor products were defined.[PMID:8384526]
publication : 8384526
definition : A tetrasachharide (four branches) glycan from which sialyl groups have been removed.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 17
GSD000057
term (main_entry) : Difucosylated tetra-antennary N-glycans
glycan_dictionary_accession : GSD000057
glytoucan_accession :
term_in_sentence : While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.[PMID: 18214858]
publication : 18214858
definition : The tetra-antennary N-linked glycans that have four GlcNAc branches linked to the core and two fucose added.
term_xref :
synonyms :
function :
disease_associations : pancreatic cancer[PMID:18214858]
wikipedia :
essentials_of_glycobiology :
GSD000058
term (main_entry) : Dimeric Lewis x
glycan_dictionary_accession : GSD000058
glytoucan_accession : G79535HZ
term_in_sentence : The carbohydrate antigen dimeric Lewis X (DimLex), which accumulates in colonic and liver adenocarcinomas, is a valuable target to develop anti-cancer therapeutics.[PMID:32957489]
publication : 32957489|31276881|12062524|15488731|1979361|8737237|17939723|7683631|11384108|11133015|17388629|15483381|12662048|3233598|18618154|21892456
definition : A six-membered glucosamine oligosaccharide consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc joined by a (1→3)-linkage.[CHEBI:61325]
term_xref : GTC:G79535HZ|GlycoEpitope:EP0093|CID:50909845|CHEBI:61325|GlycoMotif:GGM.000031
synonyms : DimLex^x|dimeric Le(x)|Lex-Lex|diLe(x)|Lewisx-Lewisx
function : cancer-associated antigen[GlycoEpitope:EP0093]
disease_associations : colonic cancer[GlycoEpitope:EP0093]|liver cancer[GlycoEpitope:EP0093]
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000059
term (main_entry) : Diphosphorylated Man6
glycan_dictionary_accession : GSD000059
glytoucan_accession : G54792LL
term_in_sentence : Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.[PMID:26503547]
publication : 26503547
definition :
term_xref : GTC:G54792LL|GlycoMotif:GGM.000054
synonyms : Diphosphorylated Man_6
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000060
term (main_entry) : Disialosyl globopentaosylceramide
glycan_dictionary_accession : GSD000060
glytoucan_accession : G97932OH
term_in_sentence : Disialosyl globopentaosylceramide (DSGb5) is often expressed by renal cell carcinomas.[PMID:31339142]
publication : 31339142|24637536|25864532|27344728| 12084983 12084983| 32567311|28205070|20663960|18214042
definition : Disialosyl globopentaosylceramide (DSGb5) is a ganglioside originally isolated from tissue extracts of renal cell carcinoma (RCC) with metastasis.[PMID:28205070]
term_xref : GlycoMotif:GGM.000082|GTC:G97932OH|GlycoEpitope:EP0098|CID:91860287|KEGG:G00181|SugarBind_Ligand:57
synonyms : DSGb5|Disialosyl Gb5|V3NeuAcIV6NeuAc-Gb5Cer|Disialosylgalactosylgloboside
function : promotes metastasis[PMID:28205070]
disease_associations : prostate cancer[PMID:24637536]|renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57]
wikipedia :
essentials_of_glycobiology :
GSD000061
term (main_entry) : Disialyl Gb5
glycan_dictionary_accession : GSD000061
glytoucan_accession : G97932OH
term_in_sentence : The major disialoganglioside antigen isolated from ACHN cells, showing specific reactivity with 5F3, was characterized unequivocally as disialosyl Gb5 (V(3)NeuAcIV(6)NeuAcGb5) by identification of the core structure as globopentaosylceramide (Gb5) after enzymatic and acid hydrolysis, and by 2-dimensional (1)H-NMR spectroscopy.[PMID: 12084983]
publication : 12084983 12084983
definition :
term_xref : GlycoEpitope:EP0098|GTC:G97932OH|CID: 91860287|SugarBind_Ligand:57|KEGG:G00181
synonyms :
function :
disease_associations : renal cell carcinoma/RCC[GlycoEpitope:EP0098]|Pyelonephritis[SugarBind_Ligand:57]
wikipedia :
essentials_of_glycobiology :
GSD000062
term (main_entry) : Disialyl I
glycan_dictionary_accession : GSD000062
glytoucan_accession : G54937EM
term_in_sentence : Here we present an example of promotion of binding of soluble-form FN from placenta or from hepatoma cells, having a specific carbohydrate epitope termed "disialyl-I," to K562 or VA13 cell surface in the presence of glycosphingolipid Gg3, which interacts specifically with disialyl-I[PMID:10640401]
publication : 10640401
definition :
term_xref : GlycoEpitope:EP0095|GTC:G54937EM|CID:91849523
synonyms : disialyl-I
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000063
term (main_entry) : Disialyl Lewis a
glycan_dictionary_accession : GSD000063
glytoucan_accession : G93400AK
term_in_sentence : Biosynthesis of disialyl Lewis a (Lea) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides.[PMID:12668675]
publication : 12668675|17760270|15231659|12668106|30716533|32050430|22467657
definition : Disialyl Lewis is a sialyl Lewis a with an additional sialic acid attached at the C-6 position of penultimate GlcNAc. [PMID:15231659]
term_xref : GTC:G93400AK |GlycoEpitope:EP0040|CID:91854138|CHEBI:155549
synonyms : disialyl Lea
function : The 2-3,2-6 disialyl Lea determinant on epithelial cells may play a role in protecting normal epithelial cells.[GlycoEpitope:EP0040]
disease_associations : Mucin antigen carrying 2-3 sialylated Le a antigen or 2-3, 2-6 disialylated Lc4 antigen in cancer patients had the lowest carbohydrate/protein ratio. Thus, the carbohydrate/protein ratio in the type 1 chain mucin antigens in sera of normal subjects is higher than that in sera of cancer patients.[GlycoEpitope:EP0040]
wikipedia :
essentials_of_glycobiology :
GSD000064
term (main_entry) : Disialyl T antigen
glycan_dictionary_accession : GSD000064
glytoucan_accession : G01614ZM
term_in_sentence : The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides.[PMID: 15701648]
publication : 29113555|17974963|33242079|12645620|15701648|26598643
definition : α-Neup5Ac-(2→6)-[α-Neup5Ac-(2→3)-β-D-Galp-(1→3)]-α-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is α.[CHEBI:71602]
term_xref : GlycoMotif:GGM.000014|GTC:G01614ZM|CID: 70698317|CHEBI:71602|GlycoEpitope:EP0023|KEGG:G00027
synonyms : di-sialyl T antigen|disialyl-T antigen|disialylated T-antigen
function : associated with von Willebrand factor(VWF) plasma levels[GlycoEpitope:EP0023]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000065
term (main_entry) : Disialylated biantennary
glycan_dictionary_accession : GSD000065
glytoucan_accession :
term_in_sentence : FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain , predominantly a disialylated biantennary structure , attached to Asn-128.[PMID:8486673]
publication : 22426998|17171781|25022802|24812685|24780636|26582205|9499382|22978794|22594947|8486673|20356825|1634621|9244386|12966096|1472054| 24243045|19579232|27943633
definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues.
term_xref :
synonyms : disialylated diantennary
function : appears in human transferrin[PMID: 24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297]
disease_associations : galactosemia.[PMID: 9499382]
wikipedia :
essentials_of_glycobiology :
GSD000066
term (main_entry) : Disialylated biantennary complex-type
glycan_dictionary_accession : GSD000066
glytoucan_accession :
term_in_sentence : The glycan was shown to be a disialylated biantennary complex type oligosaccharide N-linked to 318 Asn.[PMID:11738084]
publication : 11738084|9499382|9244386|24243045|12966096|25124522|19371135
definition : A biantennary complex glycan with two GlcNAc branches linked to the core and the addition of two sialic acid residues.
term_xref :
synonyms :
function : appears in human transferrin[PMID:24243045]|Appears in human apolipoprotein (apo) B-100.[PMID:2344297]
disease_associations : galactosemia.[PMID:9499382]
wikipedia :
essentials_of_glycobiology :
GSD000067
term (main_entry) : Disialylated fucosylated
glycan_dictionary_accession : GSD000067
glytoucan_accession :
term_in_sentence : Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.[PMID:17591618]
publication : 17591618
definition : A fucosylated glycan with two sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 45
GSD000068
term (main_entry) : Forssman antigen
glycan_dictionary_accession : GSD000068
glytoucan_accession : G80062GG
term_in_sentence : Here we report the crystal structure of the complex between SLL-2 and Forssman antigen tetrasaccharide (GalNAcα1-3GalNAcβ1-3 Galα1-4 Galβ at 3.4 √Ö resolution).[PMID:28510705]
publication : 28510705|31933576| 28134301|7021748|1802714|7512587|7747818|23325748|268649|31816281|22015168|4147161|2857159|6267170|7293775|13367419|20636540| 10460829 10460829|23255552|2675268|18955372|7020692|31784953|4114942|31273262|6257673|7696847|1916901|11169215|48262|26022515|6175621|31404475|6983878|8381954| 10431785|3257757|6792413|25039359
definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).CHEBI:85789
term_xref : GTC:G80062GG |GlycoEpitope:EP0037|CID 91825690|CHEBI:85789
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 45
GSD000069
term (main_entry) : Forssman glycolipid
glycan_dictionary_accession : GSD000069
glytoucan_accession : G80062GG
term_in_sentence : Analysis of metabolically labeled glycolipids released into the apical and basal culture medium, either as shed membrane vesicles or in budding viruses, also demonstrated the presence of the Forssman glycolipid on both apical and basolateral membranes of polarized cells.[PMID:3040119]
publication : 3040119|268649|23240079|28134301|3495590|1138893| 10460829|10506200|8855242|1955453|1933935|3355161|6773959|14573676|29898878|10431785|1747956|11214737|7423202|389939|3871816|6187373|16133832|469271|3753492|2695680|7037611|25703376|23798992|414913|1868069| 7960243
definition : A linear amino pentasaccharide comprising N-acetyl-α-D-galactosamine, N-acetyl-β-D-galactosamine, α-D-galactose, β-D-galactose and β-D-glucose residues linked sequentially (1→3), (1→3), (1→4) and (1→4).[CHEBI:85789]
term_xref : GlycoMotif:GGM.000084|GTC:G80062GG|CID:91825690|KEGG:G00095|CHEBI:85789|GlycoEpitope:EP0037|SugarBind_Ligand:86
synonyms : Forssman antigen|Globopentosylceramide
function : an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes[PMID:3495590]
disease_associations : Pyelonephritis[SugarBind_Ligand:86]|Acute cystitis[SugarBind_Ligand:86]
wikipedia :
essentials_of_glycobiology : Chapter 45
GSD000070
term (main_entry) : Fucose-containing tetraantennary
glycan_dictionary_accession : GSD000070
glytoucan_accession :
term_in_sentence : The two major N-linked oligosaccharides of Namalwa EPO were fucose-containing tetraantennary and fucose-containing triantennary structures.[PMID:2550193]
publication : 2550193
definition : A tetraantennary glycan with four GlcNAc branches linked to the core and the addition of fucose.
term_xref :
synonyms :
function :
disease_associations :
wikipedia : https://en.wikipedia.org/wiki/Forssman_antigen
essentials_of_glycobiology : Chapter 14
GSD000071
term (main_entry) : Fucosyl GM1
glycan_dictionary_accession : GSD000071
glytoucan_accession : G91532KA
term_in_sentence : Unique localization of fucosyl GM1 implicates its possible role in cell adhesion and recognition in the nervous system.[PMID:8068725]
publication : 6619101|16880505|9089399|29789847|8068725|19556222|1660040|2420639|9076515|15926079|19555091|2541996|16211870|1336587|21174147|14967068|18923900|30021910|16941490|27070150|8305235|10602885|2645049|7993838|10537341|3002616|8336147|15447995|8905401|11714535|9260862|32228455|3315641|8076384|2317201|3680254|6403518
definition : A branched amino hexasaccharide consisting of the linear sequence α-L-Fuc-(1→2)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage.[CHEBI:62686]
term_xref : GTC:G91532KA |GlycoEpitope:EP0049|CID: 53356699|CHEBI:62686
synonyms :
function :
disease_associations : small-cell lung cancer(SCLC)[GlycoEpitope:EP0049]|hepatoma[GlycoEpitope:EP0049]
wikipedia :
essentials_of_glycobiology :
GSD000072
term (main_entry) : Fucosylated asialo-biantennary
glycan_dictionary_accession : GSD000072
glytoucan_accession :
term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054]
publication : 2065054|17013932
definition : Describing a biantennary oligosaccharide that has no sialic acid component but has fucose.
term_xref :
synonyms : fucosylated asialo-diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000073
term (main_entry) : Fucosylated biantennary
glycan_dictionary_accession : GSD000073
glytoucan_accession :
term_in_sentence : The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.[PMID:17956937]
publication : 17956937|30525457|1933856
definition : a biantennary glycan with two GlcNAc branches linked to the core and the addition of fucose.
term_xref :
synonyms : fucosylated bisialo-diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000074
term (main_entry) : Fucosylated bisialo-biantennary
glycan_dictionary_accession : GSD000074
glytoucan_accession :
term_in_sentence : We found that approximately 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species.[PMID:2065054]
publication : 2065054
definition : Describing a biantennary oligosaccharide that has two sialic acid component and fucose added.
term_xref :
synonyms : Fucosylated biantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000075
term (main_entry) : Fucosylated LDN
glycan_dictionary_accession : GSD000075
glytoucan_accession : G02240AO
term_in_sentence : To date, oligomeric LDN and oligomeric fucosylated LDN (LDNF) have been found only on N-glycans from mammalian cells engineered to express Caenorhabditis elegansbeta4-GalNAc transferase and human alpha3-fucosyltransferase IX [Z. S. Kawar et al. (2005) J Biol Chem280, 12810-12819]. [PMID:16403022]
publication : 16403022|28151933|19545571|22448293
definition : An amino trisaccharide comprising an acetamido-β-D-galactose and an α-L-fucose attached to an acetamidoglucose by 1→4 and 1→3 linkages, respectively.[CHEBI:61864]
term_xref : GlycoMotif:GGM.000017|GTC:G02240AO|GlycoEpitope:EP0151|CID: 52921591|CHEBI:61864|MeSH:C488538|KEGG:G01594
synonyms : LDNF|Fucosylated lacdiNAc|LDN-F|(GalNAc)1 (GlcNAc)1 (LFuc)1
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000076
term (main_entry) : Fucosylated N-glycans
glycan_dictionary_accession : GSD000076
glytoucan_accession :
term_in_sentence : Haptoglobin , an acute phase protein , has four potential N-glycosylation sites , although it remains unknown which site is responsible for the change in fucosylated N-glycans.[PMID:[https://pubmed.ncbi.nlm.nih.gov/18214858 18214858 18214858]]
publication : 18214858|31141660|26869352|29790113|31931062
definition : The fucose from GDP-fucose is transferred to N-linked glycans.
term_xref :
synonyms :
function :
disease_associations : pancreatic cancer.[PMID: 26869352]
wikipedia :
essentials_of_glycobiology :
GSD000077
term (main_entry) : Fucosylated triantennary
glycan_dictionary_accession : GSD000077
glytoucan_accession :
term_in_sentence : Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.[PMID:2513186]
publication : 2513186|29642865|7679920|31110965|2551687|15051952|12943224
definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of fucose.
term_xref :
synonyms :
function : appears in human alpha-fetoprotein (AFP).[PMID: 7679920]
disease_associations : neoplastic diseases of the liver[PMID: 7679920] |hepatocellular carcinoma[PMID: 7679920].
wikipedia :
essentials_of_glycobiology : Chapter 43
GSD000078
term (main_entry) : Galabiosylceramide
glycan_dictionary_accession : GSD000078
glytoucan_accession : G67988RO
term_in_sentence : LacCer and its structural isomer, galabiosylceramide (Gb2, Galβ(1,4)Galβ-ceramide), are classified as ceramide dihexosides (CDH).[PMID:33360824]
publication : 33360824|29099167|25582508|2824515|4027258|32854306|32868283|31319156|29530250|27367163|2564247|27727434|10216186| 10460829|24992926|23590301|15702404|1854798|14761135|3600200|8603914|8601603|1965141|17400502|3840690|15959771|7930586|7721812|17095952|2500499|3815386|8842706|10746023|3928791|3782065|6440894
definition : A disaccharide consisting of β-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an α-linkage.[CHEBI:59314]
term_xref : GlycoEpitope:EP0113|GTC:G67988RO|CID: 5288350|KEGG:G00497|KEGG:G10645|CHEBI:59314
synonyms :
function :
disease_associations : tumor/lung[GlycoEpitope:EP0113]|tumor/gallbladder[GlycoEpitope:EP0113]|tumor/kidney[GlycoEpitope:EP0113]|tumor/pancreas[GlycoEpitope:EP0113]
wikipedia :
essentials_of_glycobiology :
GSD000079
term (main_entry) : Galactosylceramide
glycan_dictionary_accession : GSD000079
glytoucan_accession : G65889KE
term_in_sentence : Galactosylceramide improved behavioral, neuropathological, and biochemical parameters in Cln3 Cln3 Δex7/8 mice, paving the way for effective therapy for CLN3 disease and use of serum ceramide as a potential biomarker to track impact of therapies.[PMID:31393621]
publication : 31393621|19941861|9883654|33006978|26735924|22032265|18035062|25129050|2802541|1761517|28660574|475780|2302222
definition :
term_xref : GTC:G65889KE|GlycoEpitope:EP0074|SugarBind_Ligand:1|GlycoMotif:GGM.000061
synonyms : GalCer|Galactocerebroside|LC
function :
disease_associations : Pleuropneumonia[SugarBind_Ligand:1]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:1]|Lyme disease[SugarBind_Ligand:1]|Plague[SugarBind_Ligand:1]|Acquired immune deficiency syndrome[SugarBind_Ligand:1]
wikipedia :
essentials_of_glycobiology :
GSD000080
term (main_entry) : Galnac disialyl Lc4 (Hexasaccharide)
glycan_dictionary_accession : GSD000080
glytoucan_accession : G33532XU
term_in_sentence : Therefore, a new marker for prostate cancer is urgently required. We examined expression of a novel carbohydrate antigen, beta1,4-GalNAc-disialyl-Lc(4), defined by the monoclonal antibody RM2, in prostate cancer using 75 cases of radical prostatectomy specimens.[PMID: 12084983]
publication : 15704108|11278988|12084983|7509790
definition : (2R,4S,5R,6R)-5-Acetamido-2-[[(2R,3S,4R,5R,6S)-5-acetamido-4-[(2R,3R,4R,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxy-6-[(3R,4S,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CID: 91857945]
term_xref : GlycoEpitope:EP0097|GTC:G33532XU|CID: 91857945|CHEBI:149360
synonyms :
function :
disease_associations : prostate cancer[GlycoEpitope:EP0097]|renal cell carcinoma/RCC[GlycoEpitope:EP0097]
wikipedia :
essentials_of_glycobiology :
GSD000081
term (main_entry) : Gb5
glycan_dictionary_accession : GSD000081
glytoucan_accession : G99053DY
term_in_sentence : LnbB, a member of the glycoside hydrolase family 20 isolated from Bifidobacterium bifidum, was shown to release GNB from Gb5 and GA1 oligosaccharides.[PMID:25839135]
publication : 12401210|25839135|31540393|31140679|3028540|3674263|31339142|30026902|10721708|30671362|26176557|25039255|24044869|32567311|27857717|21491978|24910250|29077212|8014006|27107335|32679486|1747956|8679447|28352526|11341836|10837462| 7960243|16158941|3297853|2431136|21734356|8625206|30732055|12716912|20128040|2582447|14659673
definition : A linear amino pentasaccharide comprising D-glucose at the reducing end with a β-D-galactosyl-(1→3)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-galactosyl-(1→4)-β-D-galactosyl moiety at the 4-position.[CHEBI:141842]
term_xref : GlycoMotif:GGM.000076|GTC:G99053DY|CID:53239691|KEGG:G00097|CHEBI:62311|SugarBind_Ligand:12
synonyms : Globopentaosylceramide
function :
disease_associations : Pyelonephritis[SugarBind_Ligand:12]|Actinomycosis[SugarBind_Ligand:12|Influenza[SugarBind_Ligand:12]
wikipedia :
essentials_of_glycobiology : Chapter 11
GSD000082
term (main_entry) : GD1
glycan_dictionary_accession : GSD000082
glytoucan_accession : G81983KG
term_in_sentence : Hormonal and metabolic disturbances observed in both adult and paediatric patients with Gaucher disease type 1 (GD1) are discussed in this review. The PubMed database was used to identify articles on endocrine and metabolic disorders in GD1.[PMID:31791361]
publication : 5652802|25345088|31791361|29361370|31234327|30264864|25250137|7528216|31669751|20684311|16306603|10420586|7766692|31614613|26384672|31613991|19210136|8926633|29696051|32300455|7513313|26674302|20336376|24259734|31704237|21067946|30516933|27979707|26345314|30516941|31849452|27789132|30218706|29388611|20177787
definition :
term_xref : GlycoMotif:GGM.000105|GTC:G81983KG|CID: 91859783|KEGG:G00126
synonyms : GD1c
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000083
term (main_entry) : GD1a
glycan_dictionary_accession : GSD000083
glytoucan_accession : G46677TE | G45714BQ
term_in_sentence : Exclusive exposure of rat oligodendrocytes to GD1a, but not other gangliosides, overcomes aggregated fibronectin-induced inhibition of myelin membrane formation, in vitro, and OPC differentiation in fibronectin aggregate containing cuprizone-induced demyelinated lesions in male mice. [PMID: 28899916]
publication : 28899916|26860251|21930390|32906699|26054879|29951721|11745410|17653976|26119566|21554929|18435913|15342262|26865725|21151139|15716397|21492147|16942752|26973195|24449473|14999485|22735313|20589721|10521808|22929125|7827024|16897174|25062498|17227759
definition : A branched amino hexasaccharide consisting of the linear sequence α-Neu5Ac-(2→3)-β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to a galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GD1a.[CHEBI:59209]
term_xref : GlycoMotif:GGM.000106|GlycoMotif:GGM.000107|GTC:G46677TE|GTC:G45714BQ|CID:45266861|CHEBI:59209|GlycoEpitope:EP0056|SugarBind_Ligand:22|KEGG:G00111
synonyms : GD1alpha
function :
disease_associations : Gastroenteritis[SugarBind_Ligand:22]|Actinomycosis[SugarBind_Ligand:22]|Lazy leukocyte syndrome[SugarBind_Ligand:22]|Toxoplasmosis[SugarBind_Ligand:22]|Lyme disease[SugarBind_Ligand:22]|Botulism[SugarBind_Ligand:22]|Keratoconjunctivitis[SugarBind_Ligand:22]|Influenza[SugarBind_Ligand:22]
wikipedia :
essentials_of_glycobiology :
GSD000084

term (main_entry) : GD1b
glycan_dictionary_accession : GSD000084
glytoucan_accession : G37184KW
term_in_sentence : Gangliosides have been known to play a role in the regulation of apoptosis in cancer cells. This study has employed disialyl-ganglioside GD1b to apoptosis in human breast cancer MCF-7 cells using exogenous treatment of the cells with GD1b and endogenous expression of GD1b in MCF-7 cells.[PMID: 27144558]
publication : 27144558|24859332|18625966|7945223|32518172|26710925|31837178|20594196|30985655|11511306|1742806|11123278|7685064|2709011|33279873|22929125|9179156|17964572|8821498|32726962|26560950|2611779|10072058|20030259|16415013|10797556|11342695|8619520|21519903|16199892|23777091|30246056|10481046
definition : A branched amino hexasaccharide comprising a β-D-galactosyl-(1→4)-β-D-glucose disaccharide, the galactosyl residue of which carries β-D-galactosyl-(1→3)-N-acetyl-β-D-galactosaminyl and N-acetyl-α-neuraminyl-(2→8)-N-acetyl-α-neuraminyl disaccharide units through (2→4) and (2→3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.[CHEBI:59222]
term_xref : GlycoMotif:GGM.000108|GTC:G37184KW|CID:45266846|CHEBI:59222|GlycoEpitope:EP0059|SugarBind_Ligand:14
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 47
GSD000085
term (main_entry) : GD2
glycan_dictionary_accession : GSD000085
glytoucan_accession : G02657AK
term_in_sentence : Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. [PMID: 25440605]
publication : 28154831|32002293|32733795|28145567|31500597|31903906|29180536|28415563|25440605|30617136|25604432|30198960|31075227|31721713|30955398|32195035|27304202|31015228|31653037|31016728|30670592|30613134|29221154|30027525|29442009|31762628|30485077|25642322| 29436609|29151270|24773917|30612272|27654028|26298772
definition : A branched amino pentasaccharide consisting of a linear sequence of two α-sialyl residues, a β-D-galactosyl residue and an N-acetyl-β-D-glucosamine residue linked respectively (2→8), (2→8) and (1→4), to the galactosyl residue of which is also linked (1→4) an N-acetyl-β-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.[CHEBI:59218]
term_xref : GlycoMotif:GGM.000094|GTC:G02657AK|CID:45266844|CHEBI:59218|GlycoEpitope:EP0061|SugarBind_Ligand:88
synonyms :
function :
disease_associations : breast cancer[PMID:28415563]
wikipedia :
essentials_of_glycobiology : Chapter 11|Chatper 35
GSD000086
term (main_entry) : GD3
glycan_dictionary_accession : GSD000086
glytoucan_accession : G98544DH
term_in_sentence : In mammalian cells, the intracellular accumulation of ganglioside GD3, an acidic glycosphingolipid, contributes to mitochondrial damage, a crucial event during the apoptopic program. [PMID: 12531552]
publication : 30245960|27591028|12531552|29069780|12470841|29436609|28295752|27304202]|31138648|27288875|30446565|8721669|3903474|16081368|32743804|24372645|26792897|20890432|25330147|20581115|11174200|16040804|23783008|17368571|11023989|12901230|21807667|7061953|2231782|19423750|22632091|18202973|6392333|15896784|8261439|20052288|12847141|12486096|12118012|19912988|22795094|18655184|17043769|21395555|2472199|19776077
definition : A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential α-(2→8)-, α-(2→3)- and β-(1→4)-linkages. The oligosaccharide of ganglioside GD3.[CHEBI:59210]
term_xref : GlycoMotif:GGM.000091|GTC:G98544DH|CID:45266862|CHEBI:59210|GlycoEpitope:EP0062|SugarBind_Ligand:89|MeSH:C509062
synonyms :
function :
disease_associations : Cholera[SugarBind_Ligand:89]|Influenza[SugarBind_Ligand:89]
wikipedia :
essentials_of_glycobiology : Chapter 11
GSD000087
term (main_entry) : Globoside
glycan_dictionary_accession : GSD000087
glytoucan_accession : G00061MO
term_in_sentence : Results of TLC immunostaining of neutral glycolipids from the cDNA-transfected cells also supported the identity of the newly synthesized component as globoside. [PMID:10993897]
publication : 10993897
definition :
term_xref : GlycoMotif:GGM.000070|GTC:G00061MO
synonyms : Cytolipin K|Gb4|Globoside I|Globotetraosylceramide|P antigen
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 47
GSD000088
term (main_entry) : Globotetraosylceramide
glycan_dictionary_accession : GSD000088
glytoucan_accession : G00061MO
term_in_sentence : Here we report that PUGNAc treatment provokes globotetraosylceramide (Gb4Cer) accumulation in human umbilical vein endothelial cells (HUVEC).[PMID:28392398]
publication : 28392398|25787850|23471986|2559078|32455599|2663859|32796033|3517161|20082214|30853699|15279935|26104834|20732996|30224239|31142708|30338271|25033755|30413389|7104376|29866658|24983355|6794884|31361021|21740983|33168837|31752441|28123520|29068380|24841197|27932383|28535204|31691795|27916888|27558838|10227680|26464281|22348006|22279060|25156739|32314902|22718629|23701631|23906628|8613382|23555772|20059899|7868240
definition : An amino tetrasaccharide consisting of 2-acetamido-2-deoxy-β-D-galactopyranosyl, α-D-galactopyranosyl, β-D-galactopyranosyl, and β-D-glucopyranose units joined together in sequence by (1→3), (1→4), and (1→4) glycosidic linkages, respectively.[CHEBI:145578]
term_xref : GlycoMotif:GGM.000070|GlycoEpitope:EP0073|CID: 5288889|CHEBI:145578|SugarBind_Ligand:18|MeSH:C024032
synonyms : Gb4Cer|Gb4|Globoside|P antigen|Cytolipin K
function :
disease_associations : Actinomycosis[SugarBind_Ligand:18]|Pyelonephritis[SugarBind_Ligand:18]|Acute cystitis[SugarBind_Ligand:18]|Shigellosis[SugarBind_Ligand:18]|Lazy leukocyte syndrome[SugarBind_Ligand:18]|Influenza[SugarBind_Ligand:18]
wikipedia :
essentials_of_glycobiology : Chapter 11
GSD000089

term (main_entry) : Globotriaosylceramide
glycan_dictionary_accession : GSD000089
glytoucan_accession : G00059MO
term_in_sentence : Defects in the gene encoding α-galactosidase A lead to accumulation of globotriaosylceramide (GL3) in various cell types.[PMID:32127409]
publication : 32127409|28674962|30875019|30413389|31778662|31101366|24335674|31241709|24158513|28947349|31566927|28672034|31939530|29530250|27851774|26426881|25031264|29982630|24496231|29983334|28756410|27190352|29274327|29099167|28402705|23680766|28625968|26960552|26797827|22742555|27756537|31630715|3827883|28384397|29523338|31010832|27195818|26661087|23093409|30879639|27081853|17409683|29921669|25575293|26291612|23146289|25857295|26070511
definition : Globotriaosylceramide is a type of globoside(glycosphingolipid) which is formed by alpha linkage of galactose to lactosylceramide. The reaction is catalyzed by enzyme A4GALT.[Wiki:Globotriaosylceramide]
term_xref : GlycoMotif:GGM.000068|GTC:G00059MO|GlycoEpitope:EP0071|CID: 5279515|CHEBI:68485|MeSH:C018549|SugarBind_Ligand:27
synonyms : Gb3|GL3|Pk antigen|P^K antigen|Gb(3)|Gb_3|CD77|globotriaosylceramide|ceramide trihexoside|CTH|Trihexosylceramide
function :
disease_associations : Pyelonephritis[SugarBind_Ligand:27]|Acute cystitis[SugarBind_Ligand:27]|Shigellosis[SugarBind_Ligand:27]|Lyme disease[SugarBind_Ligand:27]|Cutaneous lesions[SugarBind_Ligand:27]|Diarrhea[SugarBind_Ligand:27]
wikipedia :
essentials_of_glycobiology :
GSD000090
term (main_entry) : Glucosylceramide
glycan_dictionary_accession : GSD000090
glytoucan_accession : G71142DF
term_in_sentence : Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321]
publication : 31265321|29290548|29627573|20919653|28427052|30550553|24415933|31914593|31051284|23073611|30146946|31619618|26840726|29750412|8065509|27412675|27840079|30611744|31353719|25661072|28686011|25803043|28865794|28154347|31466334|30242129|12531551|30639288|30864417|27711049|22764777|27905603|29077010|28744000|23555901|24115322|12803919|29204666|23628459|28851512|26136173|23563543|30110701|26572681|2193825|29926415|31727994|27479571
definition : Cerebrosides which contain as their polar head group a glucose moiety bound in glycosidic linkage to the hydroxyl group of ceramides. Their accumulation in tissue, due to a defect in beta-glucosidase, is the cause of Gaucher's disease.[MeSH:D005963]
term_xref : MeSH:D005963|GlycoMotif:GGM.000060|CHEBI:83264|GTC:G71142DF
synonyms : GlcCer|Glucocerebroside|Ceramide monohexoside|CMH
function : The structural characterization of mixed membranes made of cationic lipids and glucosylceramides may be important for developing novel immunotherapeutic tools such as vaccine adjuvants.[PMID:30611744]|Glucosylceramide (GlcCer), the initial GSL synthesized from ceramide by GCS (GlcCer synthase), is required for embryonic survival, but its role in the lung is unknown.[PMID:31265321]
disease_associations : Gaucher's Disease|Pharyngitis[SugarBind_Ligand:3]|Tracheobronchitis[SugarBind_Ligand:3]|Pleuropneumonia[SugarBind_Ligand:3]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:3]|Diarrhea[SugarBind_Ligand:3]
wikipedia :
essentials_of_glycobiology : Chapter 31
GSD000091

term (main_entry) : GM1
glycan_dictionary_accession : GSD000091
glytoucan_accession : G48558GR
term_in_sentence : GM1-induced fluidization of the phospholipid membranes and probable physical contact between bulky sugar head group of GM1 and spectrin, may explain the modulatory role of GM1 on aminophospholipid interactions with nonerythroid brain spectrin.[PMID: 29920238]
publication : 18524657|31761138|36180805|29920238|33859490|31937438|25762012|25931034|31776384|32013258|30776097|31048748|31447771|30292198|28796418|27806275|21076871|27552916|17986147|26960162|27815022|25851126|32916822|11462671|28236574|15911874|28577204|28497346|1794005|31934908|30267299|16902585|29439846|32325905|29747823|27576485|26338710|27858734|24501414|26818965|26629687|26958633|1854596|32134593|32198666|6619101
definition : A branched amino pentasaccharide consisting of the linear sequence β-D-Gal-(1→3)-β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the inner galactose via an α-(2→3) linkage. The oligosaccharide of ganglioside GM1a.[CHEBI:59208]
term_xref : GlycoMotif:GGM.000098|GTC:G48558GR|CID:196569|CHEBI:59208|GlycoEpitope:EP0050|SugarBind_Ligand:13|KEGG:G00110
synonyms : GM1 ganglioside|GM1-ganglioside
function : The branched pentasaccharide chain of ganglioside GM1 is a prominent cell surface ligand, for example, for cholera toxin or tumor growth-regulatory homodimeric galectins.[PMID:16267866]
disease_associations : GM1 gangliosidosis (GM1) [PMID: 33859490]|Gastroenteritis[SugarBind_Ligand:13]|Actinomycosis[SugarBind_Ligand:13]|Lazy leukocyte syndrome[SugarBind_Ligand:13]|Toxoplasmosis[SugarBind_Ligand:13]|Cholera[SugarBind_Ligand:13]|Botulism[SugarBind_Ligand:13]
wikipedia : https://en.wikipedia.org/wiki/GM1
essentials_of_glycobiology : Chapter 11| Chapter 14
GSD000092
term (main_entry) : GM2
glycan_dictionary_accession : GSD000092
glytoucan_accession : G79389NT
term_in_sentence : GM1 gangliosidosis has both central nervous system and systemic findings; while, GM2 gangliosidosis is restricted primarily to the central nervous system.[PMID: 27491214]
publication : 29618308|27491214|32867370|30030044|27499644|31097363|29100724|27402091|31852956|30389374|30988135|8786814|14533808|23370522|28192816|32692591|29106755|28833537|11339652|9728335|27270764|9714704|26175473|27018595|28615102|28974375|32951593|11462672|28955902|17192692|26538065|25421609|9572057|11596983|15264019|23236285|11596984|31261761|30113798|24391178|24309906|22224667|7980537|18272501|9006924|
definition : A branched amino tetrasaccharide consisting of the linear sequence β-D-GalNAc-(1→4)-β-D-Gal-(1→4)-β-D-Glc having a Neu5Ac residue attached to the galactose via an α-(2→3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.[CHEBI:59220]
term_xref : GlycoMotif:GGM.000095|GTC:G79389NT|CID: 45266845|CHEBI:59220|GlycoEpitope:EP0051|SugarBind_Ligand:39|KEGG:G00109|KEGG:G10351
synonyms :
function :
disease_associations : lung adenocarcinoma[GlycoEpitope:EP0051]|embryonal carcinoma[GlycoEpitope:EP0051]|germ cell tumor[GlycoEpitope:EP0051]|teratocarcinoma[GlycoEpitope:EP0051]|squamous cell carcinoma[GlycoEpitope:EP0051]|Gastroenteritis[SugarBind_Ligand:39]|Cholera[SugarBind_Ligand:39]|Clostridial myonecrosis[SugarBind_Ligand:39]|Tetanus[SugarBind_Ligand:39]
wikipedia : https://en.wikipedia.org/wiki/GM1_gangliosidoses
essentials_of_glycobiology : Chapter 11
GSD000093
term (main_entry) : GM3
glycan_dictionary_accession : GSD000093
glytoucan_accession : G91237TK
term_in_sentence : We also demonstrated an essential role of GM3 in murine and human auditory systems; a common pathological feature of GM3S deficiency is deafness. [PMID: 29747813]
publication : 29376491|29747813|25613425|30318083|31526872|31004109|28019668|26434718|27313500|27539856|30111401|28544772|29407985|19364317|30190430|31297734|30091781|26043887|32183071|30665141|27873002|25801320|30209782|32378734|23050851|22768242|14993837|24934090|17638075|21518140|26102277|19759399|24502144|25303960|23564406|16636105|16491123|11259118|15102521|12724312|24985965|8496625|25403557|15690123|15939439|25893133|23591593|20634908|2004380|739008|
definition : Ganglioside GM3 (d18:1/16:0) is a glycosphingolipid (ceramide and oligosaccharide)or oligoglycosylceramide with one or more sialic acids (i.e. n-acetylneuraminic acid) linked on the sugar chain. It is a component the cell plasma membrane which modulates cell signal transduction events. Gangliosides have been found to be highly important in immunology. Ganglioside GM3 carries a net-negative charge at pH 7.0 and is acidic. Gangliosides can amount to 6% of the weight of lipids from brain, but they are found at low levels in all animal tissuesGangliosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Gangliosides are very similar to globosides except that they also contain N-acetyl neuraminic acid (NANA) in varying amounts. The specific names for the gangliosides provide information about their structure. The letter G refers to ganglioside, and the subscripts M, D, T and Q indicate that the molecule contains mono-, di-, tri and quatra-sialic acid. The numbered subscripts 1, 2 and 3 refer to the carbohydrate sequence that is attached to the ceramide. In particular, 1 stands for GalGalNAcGalGlc-ceramide, 2 stands for GalNAcGalGlc-ceramide and 3 stands for GalGlc-ceramide. Deficiencies in lysosomal enzymes that degrade the carbohydrate portions of various gangliosides are responsible for a number of lysosomal storage diseases such as Tay-Sachs disease, Sandhoff disease, and GM1 gangliosidosis. The carbohydrate portion of the ganglioside GM1 is the site of attachment of cholera toxin, the protein secreted by Vibrio cholerae.[HMDB0004844]
term_xref : GlycoMotif:GGM.000090|GTC:G91237TK|CID: 5288424|CHEBI:59226|GlycoEpitope:EP0053|SugarBind_Ligand:35
synonyms :
function : Membrane stabilizer|Energy source|Energy storage|Molecular messenger:|Signaling molecule[HMDB0004844]
disease_associations : Gastroenteritis[SugarBind_Ligand:35]|Chronic gastritis[SugarBind_Ligand:35]|Toxoplasmosis[SugarBind_Ligand:35]|Peptic ulcerSugarBind_Ligand:35|Gastric cancer[SugarBind_Ligand:35]|Influenza[SugarBind_Ligand:35]|Diarrhea[SugarBind_Ligand:35]|Botulism[SugarBind_Ligand:35]
wikipedia :
essentials_of_glycobiology : Chapter 37
GSD000094

term (main_entry) : GM4
glycan_dictionary_accession : GSD000094
glytoucan_accession : G30207PZ
term_in_sentence : GM4 is synthesized by the sialylation of galactosylceramide (GalCer), while the ganglioside GM3 is synthesized by the sialylation of lactosylceramide (LacCer).[PMID:23999868]
publication : 23999868|2332419|12091485|19542236|8407875|23320941|28808804|3621237|23203271|7057115|26362868|6170387|18034482|7076644|2391348|25464080|3701369|11217952|6201236|30744426|9388026|27177620|30246056|15979459|7586078|6779816|29402905|7335153|3306476|17499534|7074082|9668345|3701884|26862430|6831238|27311552|26831445|24417799|7097284|4169231|16854400|26483798
definition : An amino disaccharide consisting of β-D-galactose having an α-N-acetylneuraminyl residue attached at the 3-position [CHEBI:63155]
term_xref : GlycoMotif:GGM.000089|GTC:G30207PZ|CID:5289366|CHEBI:63155|KEGG:G00317|SugarBind_Ligand:110
synonyms : Sialylated GalCer
function :
disease_associations : Chronic gastritis[SugarBind_Ligand:110]|Peptic ulcers[SugarBind_Ligand:110]|Gastric cancer[SugarBind_Ligand:110]
wikipedia :
essentials_of_glycobiology : Chapter 11|Chapter 15|Chapter 44|Appendix 45A
GSD000095
term (main_entry) : GP1c
glycan_dictionary_accession : GSD000095
glytoucan_accession : G93805MV
term_in_sentence : n this report, we describe an efficient convergent synthesis of the GP1c glycolipid epitope, which is one of the most complex c-series gangliosides. [PMID:19053458]
publication : 1606358|19053458|1695858|4091974|10775425|2468656|2299350|3064875|11432974| 9613831|11831845|1879553| 10699494|8969459|8474578|12031286|1304332|9153001|10564776
definition :
term_xref : GlycoMotif:GGM.000118|GTC:G93805MV
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11|Chapter 14|Chapter 27|Chapter 35|Chapter 45 |Chapter 47|Chapter 49
GSD000096
term (main_entry) : GQ1b
glycan_dictionary_accession : GSD000096
glytoucan_accession : G18625KA
term_in_sentence : Bilateral infusion of GQ1b into the hippocampus ameliorates cognitive deficits in the triple-transgenic AD mouse model (3xTg-AD).[PMID:31186474]
publication : 30798387|31186474|26704905|23677659|26984947|24184316|23804237|9819299|18514410|22189683|24859332
definition : An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59212]
term_xref : GlycoMotif:GGM.000115|GTC:G18625KA|GlycoEpitope:EP0069|CID:45266843|KEGG:G00117|CHEBI:59212
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 11
GSD000097
term (main_entry) : GQ1ba
glycan_dictionary_accession : GSD000097
glytoucan_accession : G54733XO
term_in_sentence : A few studies have reported the association of autoantibodies to GM1 or GQ1bα with Alzheimer's disease (AD) or vascular dementia.[PMID:25024341]
publication : 25024341|23717411|17870542|10702226|21137678|26748510|8662799|21274438|24649890|16580208|28124591|20095613|17507233|23565921|14505645|20930939|9201997
definition :
term_xref : GlycoMotif:GGM.000116|GTC:G54733XO
synonyms : GQ1balpha
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000098
term (main_entry) : GQ1c
glycan_dictionary_accession : GSD000098
glytoucan_accession : G99524KA
term_in_sentence : The neural specific monoclonal antibody A2B5 was found to interact with GQ1c but not with Gq1b, nor did it interact with other glycolipids such as GM1, GD1a, GD1b, GT1a, GT1b and GA1.[PMID: 6640289]
publication : 6640289| 1695858|7798936|1729139|2468656|20368669|2723647|1814411| 3064875|6085330|1613492|17883393|11831845| 10775425|8219015|8804704|1384262|7066685|2299192|9613831|10350354|1304337|9153001|11959025|8474578|2299350| 10564776|10699494|3942818|12031286|7361620
definition : Alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp is a member of neuraminic acids and an amino octasaccharide.[CID: 91860352]
term_xref : GlycoMotif:GGM.000117|GTC:G99524KA|CID: 91860352|CHEBI:145645|KEGG:G00121
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 46
GSD000099
term (main_entry) : GT1a
glycan_dictionary_accession : GSD000099
glytoucan_accession : G68110IF
term_in_sentence : GT1a mimicry was found in the lipo-oligosaccharides of strain ICDCCJ07002 and ICDCCJ07004; but a combination of GM3/GD3 mimics was observed in ICDCCJ07001, although this patient had anti-GT1a IgG antibodies.[PMID:26197476]
publication : 12023422|32623212|26197476|9585812|29747820|23804237|11993188|31683059|19631994|9742882|29709941|8971119|8706663|893404|31829433|8910600|30600291|29319803|26176883|29063860|6766128|31602715|29808463|30711390|29847988|30116054|28187751
definition : A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.[CHEBI:59215]
term_xref : CID:45266863|GlycoMotif:GGM.000110|GTC:G68110IF|GlycoEpitope:EP0066|KEGG:G00112|CHEBI:59215
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000100
term (main_entry) : GT1a alpha
glycan_dictionary_accession : GSD000100
glytoucan_accession : G02149VR
term_in_sentence : A new class of gangliosides, GT1a alpha and GQ1b alpha, were initially identified as cholinergic neuron-specific antigens in bovine brain. [PMID:8082783]
publication : 7710562|8082783|10972137|9468624|9143254|8221098|9679279|11368158|11878808
definition :
term_xref : GlycoMotif:GGM.000111|GTC:G02149VR|GlycoEpitope:EP0111|CID: 91851751|CHEBI:156678|KEGG:G00128
synonyms : GT1aa
function : GT1a alpha was a cholinerginic-specific antigen.[GlycoEpitope:EP0111]
disease_associations :
wikipedia :
essentials_of_glycobiology :